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Spinal cord injury (SCI) is a devastating condition that affects people in the
prime of their lives. A myriad of vascular events occur after SCI, each of which
contributes to the evolving pathology. The primary trauma causes mechanical
damage to blood vessels, resulting in hemorrhage. The blood-spinal cord barrier
(BSCB), a neurovascular unit that limits passage of most agents from systemic
circulation to the central nervous system, breaks down, resulting in inflammation,
scar formation, and other sequelae. Protracted BSCB disruption may exacerbate
cellular injury and hinder neurobehavioral recovery in SCI.
In these studies, angiopoietin-1 (Ang1), an agent known to reduce vascular
permeability, was hypothesized to attenuate the severity of secondary injuries of
SCI. Using longitudinal magnetic resonance imaging (MRI) studies (dynamic
contrast-enhanced [DCE]-MRI for quantification of BSCB permeability, highresolution anatomical MRI for calculation of lesion size, and diffusion tensor imaging
for assessment of axonal integrity), the acute, subacute, and chronic effects of Ang1
administration after SCI were evaluated. Neurobehavioral assessments were also
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performed. These non-invasive techniques have applicability to the monitoring of
therapies in patients with SCI.
In the acute phase of injury, Ang1 was found to reduce BSCB permeability
and improve neuromotor recovery. Dynamic contrast-enhanced MRI revealed a
persistent compromise of the BSCB up to two months post-injury. In the subacute
phase of injury, Ang1’s effect on reducing BSCB permeability was maintained and it
was found to transiently reduce axonal integrity. The SCI lesion burden was
assessed with an objective method that compared favorably with segmentations
from human raters. In the chronic phase of injury, Ang1 resulted in maintained
reduction in BSCB permeability, a decrease in lesion size, and improved axonal
integrity.
Finally, longitudinal correlations among data from the MRI modalities and
neurobehavioral assays were evaluated. Locomotor recovery was negatively
correlated with lesion size in the Ang1 cohort and positively correlated with diffusion
measures in the vehicle cohort. In summary, the results demonstrate a possible role
for Ang1 in mitigating the secondary pathologies of SCI during the acute and chronic
phases of injury.
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CHAPTER 1:

INTRODUCTION
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Spinal Cord Injury
Spinal Cord Injury (SCI) is a devastating condition that affects people in the
prime of their lives. 256,000 Americans currently live with SCI and 12,000 more are
injured each year. The estimated lifetime medical care expenses of SCI patients
range from $500,000 to $3,000,000 depending on the level of SCI and patient’s
age at the time of SCI (Priebe et al., 2007). The mainstay therapy for SCI remains
surgical decompression of the spinal cord and physical rehabilitation. High dose
methylprednisolone is the only widely-used pharmacologic treatment approach to
SCI (Bracken, 2002; Baptiste and Fehlings, 2007) yet its efficacy remains
controversial (Hugenholtz, 2003) and thus has not been approved by the Food and
Drug administration (FDA). A small number of clinical trials focusing on
neuroprotection and regeneration are underway (Hall and Springer, 2004; Sykova
et al., 2006; Faden and Stoica, 2007; Alper, 2009). Due to limited therapeutic
options beyond supportive care, there is an urgent need for novel treatment
approaches that tackle multiple aspects of SCI pathophysiology.
The primary injury in SCI leads to axonal damage and mechanical
disruption of the blood vessels within and surrounding the spinal cord (Mautes et
al., 2000). Hemorrhage occurs immediately after SCI (Nelson et al., 1977). In
addition, the blood-spinal cord barrier (BSCB) is further compromised due to the
release of inflammatory cytokines (e.g. IL-1β, TNFα, and IL-6) by activated central
nervous system (CNS) cells (e.g. astrocytes and microglia) (Jones et al., 2005;
Tian et al., 2007). These inflammatory cytokines cause local edema and signal the
intravasation of neutrophils from the systemic vasculature into the parenchyma.
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This process is partly mediated by increased expression of adhesion molecules
(e.g. ICAM and VCAM) on the surface of vascular endothelial cells that facilitate
diapedesis, chemotaxis, and attachment of neutrophils via their cell surface
integrins (Carlos and Harlan, 1994). Neutrophils cause cellular damage via the
release of free oxygen radicals that lead to lipid peroxidation, cell death, and
further inflammation (Carlson et al., 1998; Juurlink and Paterson, 1998; Fleming et
al., 2006). This cascade of molecular and cellular events that follows the primary
injury is collectively termed “secondary injury” (Anderson and Hall, 1993) and
causes tissue damage away from the site of injury and prevents recovery of
neurological function (Coleman and Perry, 2002; Gimenez y Ribotta et al., 2002;
Hagg and Oudega, 2006). The majority of SCI treatments target the secondary
injury events in order to retard or prevent the downstream sequelae.

Role of Vascular Permeability in Spinal Cord Injury
A myriad of vascular events occur after SCI, each of which contributes to
the evolving pathology. The primary trauma causes mechanical damage to blood
vessels, resulting in hemorrhage primarily in gray matter (Amar and Levy, 1999).
The BSCB breaks down, leading to inflammation, scar formation, and other
sequelae (Mautes et al., 2000). Popovich et al. and Noble et al. previously showed
that the BSCB remains compromised up to 28 days post-SCI and that this
disruption extends both caudally and rostrally beyond the site of injury (Noble and
Wrathall, 1989; Popovich et al., 1996). Studies from our laboratory, based on
dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), have
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confirmed these observations and demonstrated that the permeability remains
elevated two months after injury even when the tissue appears normal on
conventional MRI (Cohen et al.). Protracted BSCB disruption may exacerbate
cellular injury and hinder neurobehavioral recovery.
The BSCB is a specialized structure at the level of capillaries that protects
the spinal cord from potentially toxic agents found in the systemic circulation.
Some of the components of the BSCB include: tight junction proteins between
adjacent vascular endothelial cells, a basal lamina, a layer of smooth
muscle/pericyte cells that sheathe the vascular endothelium, and a negativelycharged glycocalyx. Studies from our laboratory have identified a significant
correlation between reduced BSCB permeability and improved open field
locomotor scores in our rat model of SCI (Cohen et al.), suggesting the potential
importance of restoring barrier integrity in SCI.

Angiopoietin-1
Angiopoietin-1 (Ang1) is a soluble ligand secreted by pericytes, astrocytes,
mast cells, and stromal cells (Acker et al., 2001; Sundberg et al., 2002; Hori et al.,
2004; Nakayama et al., 2004). Ang-1 binds to and phosphorylates Tie-2, a receptor
tyrosine kinase on endothelial cells (Davis et al., 1996). Activation of Tie-2
promotes endothelial cell survival via the phosphoinositide 3-kinase (PI3K) survival
pathway (Peters et al., 2004). Tie-2 phosphorylation also activates A-20 binding
inhibitor of nuclear factor-kappa B (NF-κB) activation (ABIN-2), which reduces the
expression of adhesion molecules on the vascular endothelial cell surface (Tadros

4

et al., 2003). Selective inactivation of NF-κB has been shown to improve
neuromotor recovery in rat and mouse models of SCI (Brambilla et al., 2005; Rafati
et al., 2007). Ang-1 is believed to reduce vessel permeability by a host of
mechanisms, including increased pericyte coverage and tight junction protein
upregulation in vascular endothelium (Liu et al., 2000; Iizasa et al., 2002;
Stoeltzing et al., 2003; Zhu et al., 2006). In short, Ang-1 activation of Tie-2
stabilizes blood vessels by reducing vascular permeability (Papapetropoulos et al.,
1999; Thurston et al., 1999; Thurston et al., 2000).
Human Ang1 has 89% homology with rat Ang1 and is cross-reactive with rat
Tie-2 receptor. Recombinant human Ang1 was shown to reduce vessel leakiness
and inflammation in a dose-dependent manner in rat models of diabetic retinopathy
(Joussen et al., 2002) and in hCG-induced testicular inflammation (Haggstrom
Rudolfsson et al., 2003). The vascular changes in these disease models are
similar to those observed in the secondary injury of SCI (e.g. increased vessel
permeability and inflammation). Ang1 has been shown to reduce the permeability
of adult vasculature (Thurston et al., 2000) and central nervous system (CNS)
vasculature, specifically the blood-brain barrier (Zacharek et al., 2007) and BSCB
(Han et al., 2010). However, it should be noted that Ang1 has been demonstrated
to act on other components of the nervous system as well, namely neurons. For
instance, Ang1 has been shown to induce neurite outgrowth in cultured dorsal root
ganglion cells (Kosacka et al., 2005; Kosacka et al., 2006). Thus, although the
effects of Ang1 are known to be primarily mediated through the endothelial-specific
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Tie-2 receptor, other CNS cells expressing Tie-2 may be affected by exposure to
Ang1.

Angiopoietin-1 in Spinal Cord Injury
At present, there is only one published study that has investigated the role
of Ang1 in experimental SCI, in a mouse T9 contusion model (Han et al.). This
investigation demonstrated effects of Ang1 at the injury epicenter, including
significantly increased vascularity and significant attenuation of vascular
permeability, locomotor deficits, white matter loss, CD3-positive T cell infiltration,
and inflammation (Han et al.). However, understanding of the role of Ang1 beyond
the lesion site is lacking. In addition, the longitudinal effects of Ang1 administration
after SCI remain unclear. Further study is warranted to better understand the
potentially beneficial and detrimental roles, if any, of Ang1 in SCI.

Central Hypothesis
I hypothesize that Ang1 attenuates the severity of three secondary
injuries of SCI (compromised BSCB, SCI lesion, and axonal damage) and
improves neurobehavioral recovery after the injury.

Specific Aims
In order to test this hypothesis, three specific aims are proposed in an
experimental rat model of thoracic level seven (T7) contusion SCI. Animals will be
divided into two cohorts, experimental (Ang1-treated) and control (vehicle-treated).

6

Specific Aim 1: Investigate the effect of acute administration of Ang1
on BSCB permeability in the acute (2 days post-SCI), subacute (7 and 14
days post-SCI), and chronic (28, 42, and 56 days post-SCI) phases of injury.
Blood-spinal cord barrier permeability will be quantified in the epicenter and
perilesional regions based on in vivo DCE-MRI. Using an established twocompartment pharmacokinetic model, DCE-MRI data will be used to quantify
BSCB permeability (Bilgen and Narayana, 2001; Bilgen et al., 2002; Cohen et al.,
2009). DCE-MRI will allow for non-invasive spatial tracking of changes in BSCB
permeability. I hypothesize that, compared to the control cohort, decreased BSCB
permeability will be observed in the Ang1 cohort.
Specific Aim 2: Investigate the effect of acute administration of Ang1
on spinal cord lesion size in the acute (2 days post-SCI), subacute (7 and 14
days post-SCI), and chronic (28, 42, and 56 days post-SCI) phases of injury.
Lesion size will be quantified in the epicenter and perilesional regions based on in
vivo high-resolution rapid acquisition relaxation enhancement (RARE) MRI scans.
A new histogram-based approach will be used to objectively assess lesion size
and this approach will be evaluated against results from human raters. I
hypothesize that, compared to the control cohort, decreased SCI lesion size will be
observed in the Ang1 cohort.
Specific Aim 3: Investigate the effect of acute administration of Ang1
on axonal integrity in the subacute (7 and 14 days post-SCI) and chronic (28,
42, and 56 days post-SCI) phases of injury and on neurobehavioral outcomes
in the acute (2 days post-SCI), subacute, and chronic phases of injury. Fiber

7

tract integrity in the epicenter and perilesional regions will be quantified based on
in vivo diffusion tensor imaging (DTI) scans. Neurobehavioral outcomes will be
evaluated based on standard assessments. I hypothesize that, compared to the
control cohort, increased axonal integrity and improved neurobehavioral recovery
will be observed in the Ang1 cohort, and that these measures will be correlated
with each other.

Significance
There is considerable evidence that compromised vasculature plays an
important role in initiating pathophysiological events that lead to secondary injury in
SCI. There is also some evidence that Ang1 plays an important role in stabilizing
vasculature and promoting neuroprotection. The outcome of any treatment is
traditionally assessed using invasive techniques such as histology. Such studies
provide invaluable information about the injury and mechanism. However, they are
not directly applicable to humans, especially in the context of disorders of the
central nervous system. The strength of the current studies is their noninvasive
and multi-modal nature. For these studies I employed (1) MRI to determine the
effects of Ang1 on BSCB compromise, lesion size, and axonal integrity and (2)
neurobehavioral assessment to determine the effects of Ang1 on locomotion, axial
stability, coordination, sensory-motor integration, rearing behavior, and persistent
mechanical allodynia. Both types of methodologies (i.e., MRI and neurobehavioral
evaluation) are non-invasive and serially use the animals as their own control, and
could be adapted for human SCI patients in the assessment of promising
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treatments. Overall, these studies are hypothesized to provide evidence to support
a role for Ang1 as a potential therapeutic agent in the management of SCI.
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CHAPTER 2:

MATERIALS AND METHODS
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Ethics
The protocol employed in these studies was approved by the institutional
Animal Welfare Committee. All animal procedures were performed according to the
NIH Guide for the Care and Use of Laboratory Animals.

Overview
These studies investigate the role of Ang1, administered acutely after injury,
on various aspects of SCI pathology (e.g., compromised BSCB, SCI lesion, and
reduced axonal integrity) and neurobehavioral recovery. In order to longitudinally
evaluate changes in these pathologies and functional outcomes, animals were
serially assayed by MRI and neurobehavioral testing, respectively.

Justification for number of animals
Forty-three male Sprague-Dawley rats were used in these studies (n=40 for
experimental investigation and n=3 to provide baseline data for DCE-MRI
analysis). Table 2.1 summarizes the animals used for each component of these
studies. Based on preliminary studies in our laboratory, power analysis was
performed to determine the number of animals required to achieve statistical
significance in the proposed studies (α=0.05) with power = 0.8. In order to detect
changes in MRI metrics (lesion size from anatomical MRI scans, Kps parameter
from DCE-MRI scans, and metrics from diffusion tensor imaging (DTI) scans), n=8
animals/treatment were required. In order to detect changes in neurobehavioral
scores, n=12 animals/treatment were required. It would be ideal to scan the
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animals daily; however, anesthetizing them everyday would lead to an
unacceptably high mortality rate. It is our experience that scanning during the
acute phase of SCI leads to an extremely high mortality rate; this is one reason
why studies were separated into acute studies at a single time point and serial
studies. The aim of this study was to evaluate the effect of acutely administered
Ang1 in experimental SCI; thus all animals in SCI studies (single study and serial
study) received a T7 contusion SCI, and a sham group was not necessary.

Group

No. Spinal Cord Intraspinal
Animals ManipulationMicroinjection

1, single
8
study

Purpose

Measurements

Treatment
MRI scans and
control
neurobehavioral
Effect of single
assessment at 2
2, single
8
Ang1
dose in acute
days post-SCI
study
SCI, RF coil
phase
implantation
3, serial
Treatment
MRI scans and
12
Vehicle
study
control
neurobehavioral
Effect of single assessment at 7,
4, serial
dose in acute 14, 28, 42, and 56
12
Ang1
study
days post-SCI
phase
Uninjured
Uninjured,
MRI scans 7 days
control for
5
3
None
RF coil
DCE-MRI
post-implantation
implantation
analysis
Table 2.1 - Experimental design. Ang1 = angiopoietin-1, DCE = dynamic
contrast-enhanced, MRI = magnetic resonance imaging, RF = radiofrequency, SCI
= spinal cord injury
Vehicle

Spinal cord injury
All surgical procedures were performed as described previously (Herrera et
al., 2009). Male Sprague-Dawley rats (N=40, 300-350 g) were anesthetized with
spontaneous inhalation of isoflurane (4%). They were then intubated and
maintained under anesthesia by mechanical ventilation with 2-2.5% isoflurane,
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30% oxygen and 67.5-68% air through a rodent ventilator (Model 683, Harvard
Apparatus, Holliston, MA). The vertebral processes of the sixth and seventh
thoracic vertebrae (T6 and T8) were secured to stabilize the vertebral column
(Figure 2.1). The spinal cord at the level of T7 was exposed by removing the T7
spinous process and the corresponding laminae. A moderately severe contusion
injury (150 kdyne force, 1 sec dwell time) was produced using the Infinite Horizon
Impactor (Precision Systems and Instrumentation, LLC, Lexington, KY).

Figure 2.1 – Stabilization of vertebral column at T6 and T8 prior to spinal
cord injury. The impactor tip is shown placed directly above the exposed T7
level of the spinal cord.

SCI animals were divided into two groups (n=16 single study and n=24
serial study) and each group was further divided in half (n=8 single study, Ang1
treatment; n=8 single study, vehicle treatment; n=12 serial study, Ang1 treatment;
n=12 serial study, vehicle treatment). These animals received a single
microinjection (1.5 µL) of either purified rat albumin (1 µg/µL, Pel-Freez Biologicals,
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Rogers, AR) or carrier-free recombinant human Ang1 diluted in 0.1% rat albumin
(0.67 µg/µL, R&D Systems, Minneapolis, MN) into the lesion site immediately after
SCI, at a depth of 1.2 mm and a rate of 0.5 µL/min through a 70 µm-diameter glass
pulled-tip pipette driven by a picospritzer (Parker Hannafin Corp., Fairfield, NJ).
The Ang1 dose of 1 µg was selected based on previous results from other studies
of blood-organ barrier in immune privileged sites (retina and testis) in rat, which
found this dose of Ang1 has led to measurably decreased vascular permeability
(Joussen et al., 2002; Haggstrom Rudolfsson et al., 2003). Concerns regarding
Cain et al.’s finding of a therapeutic effect of serum albumin treatment in SCI (Cain
et al., 2007) are allayed by the fact that the dose of albumin we employed as
vehicle control is 133-fold less than that used by Cain et al.
For improved signal-to-noise ratio (SNR) of MRI scans, a radiofrequency
(RF) coil (35 mm length x 11 mm width x 7 mm height) was implanted
subcutaneously over the injury site without touching the spinal cord (Fenyes and
Narayana, 1998) (Figure 2.2). The coils had been coated with a biologically inert,
biomedical grade silicone elastomer (Silastic® MDX4-4210, Dow Corning, Midland,
MI) to electrically isolate it from the tissue and were then sterilized in a gas
sterilizer (AN74i Anoprolene Gas Sterilization, Andersen Sterilizers, Inc., Haw
River, NJ) prior to implantation. The Lamor frequency for the 7 T field strength of
the MRI magnet used is 300 MHz and the resonating frequency of the implanted
coil was designed to function at this frequency. The dorsal wound was closed in
two layers (paraspinal muscles interiorly and skin exteriorly).
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Figure 2.2 – Implantation of radiofrequency coil after spinal cord injury.
The coil improves signal-to-noise ratio on magnetic resonance imaging scans.

For intravenous delivery of gadodiamide (Gd, trademarked as Omniscan,
GE Healthcare, Princeton, NJ) during the DCE-MRI scans in animals in groups 1
and 2, the right jugular vein was cannulated and silicone tubing (Instech Solomon,
Plymouth Meeting, PA) was implanted and the incisions were closed. The silicone
tubing was extended outside of the animal’s neck area in order to allow vascular
access for delivery of the contrast agent during the DCE-MRI scan. For animals in
groups 3 and 4 (serial studies), the right jugular vein was cannulated, and a
vascular port with silicone tubing (Instech Solomon, Plymouth Meeting, PA) was
implanted (Figure 2.3), and the incisions were closed. To ensure patency of the
jugular port and connected tubing over the 8-week duration of the serial studies,
0.2 mL of 0.9% saline was injected into the port before and after each scan. If
resistance on the plunger of the syringe was felt during administration of the saline
bolus, the port or tubing was assumed to be blocked and the animal was excluded
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from further MRI scanning. Final confirmation of patency of the jugular port was
assessed after the DCE-MRI scan, in which contrast agent could be readily
observed in the vasculature.

Figure 2.3 – Vascular port implantation for access to systemic
vasculature during dynamic contrast-enhanced magnetic resonance
imaging scans. For the serial studies (animals in groups 3 and 4). Arrow
indicates subcutaneous bulge of implanted vascular port.

Post-SCI animal care
Animals were allowed to recover in warmed cages and saline was
administered subcutaneously. Animals also received subcutaneous cefazolin (15
mg/kg, West-Ward Pharmaceuticals, Eatontown, NJ) twice daily for 7 days,
Buprenex (0.01 mg/kg, Hospira Inc., Lake Forest, IL) twice daily for 5 days, and
0.9% saline (3-5 mL, Hospira Inc., Lake Forest, IL) twice daily for 5 days. Urinary
bladders were manually expressed twice daily until spontaneous return of
urination. Zinc oxide ointment (E. Fougera & Co., Melville, NY) was applied if the
skin appeared to be irritated. Triple antibiotic ointment (Alpharma USPD Inc.,
Baltimore, MD) was applied on wounds or broken skin. When necessary, rats were
gently bathed with hypoallergenic shampoo (HydroSurge, Carlsbad, CA) and warm
water.
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Neurobehavioral assessment
From a clinical perspective, regaining neuromotor function and the ability to
perform activities of daily living are the most tangible benefits of SCI therapy
(Estores, 2003). In order to assess the effects of Ang1 on neurobehavioral
recovery post-SCI, five neurobehavioral assays were performed. All assays were
performed by two independent observers who were blinded to the treatment
groups. The neurobehavioral assessments were performed prior to injury, and prior
to each MRI scan (i.e., post-SCI neurobehavioral data was recorded on the same
day of MRI scans) to reduce any potentially interfering effects of the anesthesia
using during the scans.
In group 1-4 animals, open field locomotion was assessed using the BassoBeattie-Bresnahan (BBB) scale (range of scores: 0-21) (Basso et al., 1995). To
perform the BBB assessment, the animal was placed in an open field and
encouraged to continuously move. If no hindlimb movement was observed, a score
of zero was given; if a slight movement of one or two joints was seen, then a score
of one was assigned. The scores increased as the animal displayed greater
stability, coordination, and functional recovery. The highest score of 21 was given if
the rat displayed “coordinated gait, consistent toe clearance, parallel paw position
throughout stance, consistent trunk stability, and a consistently lifted tail.”
Although group 1-2 animals only underwent the BBB assay, group 3-4
animals received additional neurobehavioral assessments. Once the BBB score
was ≥5 (this usually occurred by 7-14 days post-SCI and indicates “slight
movement of two joints and extensive movement of the third”), axial stability and
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postural control was tested with the inclined plane test (Rivlin and Tator, 1977).
Animals were placed on an inclined plane whose angle of elevation could be
adjusted. The maximum angle of incline for which the rat could maintain his
position for 5 sec without slipping was recorded.
Once the BBB score was ≥9 (this usually occurred by 14-28 days post-SCI
and indicates “plantar placement of the paw with weight support in stance only
(i.e., when stationary); or occasional, frequent, or consistent weight supported
dorsal stepping and no plantar stepping”), mechanical allodynia was assayed with
the vonFrey hair filament test (Peng et al., 2006). Fifteen minutes prior to
evaluation, rats were placed in clear Plexiglas boxes on an elevated platform with
mesh surface, for acclimation. After this period, an electronic vonFrey
anesthesiometer (IITC Life Science, Inc., Woodland Hills, CA) was used to probe
forepaw sensitivity. The filament was alternatingly applied to the plantar surface of
each forepaw and the maximum pressure required to elicit paw withdrawal was
recorded. This process was performed five times and the highest and lowest
pressure recordings for each paw were discarded; data analysis was carried out on
the remaining three values for each forepaw. Based on previous work in our lab
(Sundberg, 2009), chronic pain was defined as mean threshold values at days 28,
42, and 56 pot-SCI being lower than that at baseline (pre-SCI), for both forepaws.
Once the BBB score was ≥12 (this usually occurred by 14-28 days post-SCI
and indicates “frequent to consistent weight supported plantar steps and
occasional forelimb-hindlimb coordination”), animals were assessed for forelimbhindlimb coordination, sensory-motor integration, and fine motor control with the
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grid walk test (Bresnahan et al., 1987). Animals were placed on a walkway grid
with 2 cm x 2 cm wide gaps. Animals had to correctly place their limbs on the grid
bars in order to traverse the walkway. A minimum of 30 steps was counted and the
number of errors (i.e. footfalls) of either the hindlimb or forelimb was also counted
during that time. The data from the grid walk test was analyzed as a ratio of
footfalls to total steps and reported as the percent of footfalls.
Starting with the 2-week post-SCI time point, computerized activity boxes
were used to assess fine motor movements, ambulation, and rearing. Animals
were placed in activity chambers for 15-minute testing periods and data were
collected using the software and hardware provided by the Photobeam Activity
System (PAS) with Flexfield (San Diego Instruments, Inc., San Diego, CA). The
PAS acquired data reflecting the animal’s movements within the activity chamber
by recording the number of times photobeams were obstructed in a x-, y-, and zaxis oriented grid system (Mills et al., 2001). Measures from the computerized
activity boxes included gross motor movement, fine motor movement, and rearing
activity.

Animal preparation for MRI scans
Animals underwent MRI scans on the days specified in Table 2.1. On the
day of MRI scan, animals were anesthetized with an induction dose of 4%
isoflurane and were then intubated and mechanically ventilated with 2-2.5%
isoflurane, 30% oxygen and 67.5-68% air through a rodent ventilator (Model 683,
Harvard Apparatus, Holliston, MA) for the duration of the scan (approximately 2.5
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hours). Silicone tubing (Instech Solomon, Plymouth Meeting, PA) attached to a
syringe containing Gd at a concentration of 0.1 mmol/kg body weight (0.2 mL/kg
body weight) was attached to the tubing protruding from the animal’s neck (for
animals in groups 1 and 2) or to the subcutaneous vascular port (for animals in
groups 3 and 4).
Animals were placed in the supine position on a Plexiglas bed and a 35 mm
x 40 mm coil that was inductively coupled to the implanted RF coil was placed
under the rat. The respiratory rate and rectal temperature were monitored
throughout the experiment with a MRI-compatible physiologic monitoring unit
(Model 1025, SA Instruments, Inc., Stonybrook, NY). A pulse oximeter (Model
8600V, Nonin Medical Inc., Plymouth, MN) was used to monitor heart rate and
oxygen levels. For the duration of the experiments, a heating system (Model
11007B, SA Instruments, Inc., Stonybrook, NY) was used to maintain the body
temperature at 36 °C.

MRI data acquisition
All MR studies were performed on a 7 Tesla Bruker scanner (70/30 USR
Bruker Biospec, Karlsruhe, Germany) using a 116 mm shielded gradient insert that
is capable of producing maximum gradient amplitude of 400 mT/m with 80 µs rise
time. Prior to performing each MRI scan, a quality assurance scan that included
SNR and magnetic field homogeneity assessment was performed, as described
elsewhere (Cohen et al., 2009). After initially shimming the magnet using the
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manufacturer’s

autoshim

routine

(ParaVision,

Bruker

Biospec,

Karlsruhe,

Germany), manual adjustment of the X, Y, Z, and Z2 shims was performed.
Following the acquisition of a tri-pilot scan (for locating the spinal cord),
either anatomical imaging (group 1 and 2 animals) or diffusion tensor imaging (DTI,
group 3 and 4 animals) was performed. DTI scans were not performed in group 1
and 2 animals because of the concerns about high mortality rate due the long scan
times. In addition, the poor tissue contrast at this acute time point precludes
meaningful analysis of axonal integrity in the injured area. DTI data were acquired
using an echo planar imaging (EPI) readout sequence with 4 shots, repetition time
(TR) = 3000 ms, echo time (TE) = 39.73 ms, receiver bandwidth of 200 kHz, 42
gradient directions (using a rotationally invariant encoding scheme with 21 positive
and 21 negative encoding directions that were balanced and unbiased (Madi et al.,
2005)), acquisition matrix of 128x128, square field of view (FOV) of 2.62 cm x 2.62
cm, 25

contiguous 1-mm-thick slices, and b-factor = 842 sec/mm2 (gradient

amplitude = 386 mT/m, gradient pulse duration δ = 2 ms and gradient pulse
separation Δ = 22 ms). DTI images were reconstructed to 256x256. The DTI scan
lasted approximately 35 minutes.
The high-resolution anatomical images were acquired with a dual-echo
rapid acquisition relaxation enhancement (RARE) scan using TR = 3200 ms, TE =
21.2 ms and 63.6 ms, acquisition matrix = 256x256, FOV = 2.62 cm x 2.62 cm, and
35 contiguous 1-mm-thick slices. The RARE scan lasted approximately 15
minutes.
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Finally, the DCE-MRI scan was performed (Cohen et al., 2009; Patel et al.,
2009). Two repetitions of pre-contrast T1-weighted spin echo, axial images were
acquired using TR = 500 ms, TE = 10.4 ms, acquisition matrix = 256x128 (zerofilled to 256x256), FOV = 2.62 cm x 2.62 cm, and 35 contiguous 1-mm-thick
slices). Then, without moving the animal, a bolus of Gd was injected in less than 5
seconds into the cannulated jugular vein via the silicone tubing (group 1 and 2
animals) or vascular port (group 3 and 4 animals). Immediately following the
administration of Gd, T1-weighted images were continuously acquired for an
additional 18 repetitions, each with a temporal resolution of 4 minutes, as part of
the DCE-MRI scan. The DCE-MRI scan lasted approximately 80 minutes.

Animal handling after MRI scans
After the MRI scans, rats were weaned off of the ventilator and anesthesia,
until they breathed spontaneously. They were then extubated and placed under a
heating lamp for 15 minutes.

MRI data analysis: inclusion/exclusion criteria and definition of spatial
regions
Data were excluded if the SCI injury was too severe and resulted in
observable illness (e.g. lack of appetite) or abnormal pathology on MRI as
indicated by extended spatial spread of injury on RARE scans (loss of gray-white
matter contrast in >10 slices at 2 days pos-SCI or in >15 slices at 7 days postSCI). In addition, data were excluded based on neurobehavioral criteria. An injury
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was considered too light if the BBB score was >5 at 3 days post-SCI and too
severe if the BBB score was <5 at 14 days post-SCI.
In regards to MRI-based identification of spinal cord spatial regions, the first
step entailed identification of the MRI epicenter slice. This slice was verified by two
independent trained observers as the single slice containing the largest lesion
(RARE scan) and greatest extravasation of Gd into the spinal cord parenchyma
(DCE-MRI scan). If the observers’ choice of epicenter slice did not match, the
observers conferred until the epicenter slice was agreed upon. Next, the length of
the spinal cord was divided into three spatial regions: epicenter region (SCI
epicenter slice, 2 slices immediately caudal to the epicenter slice, and 2 slices
immediately rostral to the epicenter slice), caudal region (slices 3-6 mm caudal to
the epicenter slice), and rostral region (slices 3-6 mm rostral to the epicenter slice),
as indicated in Figure 2.4. The size of the regions corresponds to those of
previously published reports (Cohen et al., 2009; Patel et al., 2009).

Dorsal

Ventral

Caudal
Region
(3-6 mm)

Epicenter
Region
(0±2 mm)

Rostral
Region
(3-6 mm)

Figure 2.4 - Definition of spatial three spatial regions for MR image-based
analyses. This set of images was taken from a 2 day post-SCI anatomical
scan.
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MRI data analysis: DCE-MRI scans (BSCB compromise and permeability)
Frank enhancement in tissue on post-contrast DCE-MRI scans represents areas of
compromised BSCB that allow for extravasation of Gd from systemic vasculature
into the spinal cord parenchyma. Data were separately analyzed for enhancing and
normal-appearing tissue areas. Unlike previous studies that relied on objective
segmentation of these regions from the DCE-MRI scans (Cohen et al., 2009; Patel
et al., 2009) based on what was visually observable, these studies employed a
slice-by-slice objective technique that is solely dependent on the signal intensity
distribution (SID) of the total spinal cord cross sectional area. First, a region of
interest (ROI) enclosing the entire spinal cord, but excluding peripheral
cerebrospinal fluid (CSF), was drawn. Next, the SID was obtained. Enhancing
tissue areas were defined as pixels in the entire spinal cord ROI whose signal
intensity was above the 35% threshold, or in other words, in the upper 65% of the
SID (Figure 2.5). This threshold was determined by two independent and trained
observers as the threshold that best corresponded to visual areas of frank contrast
enhancement on the DCE-MRI scans.

Dorsal

Ventral
Caudal

Epicenter

Rostral

Figure 2.5 – Identification of enhancing and non-enhancing tissue areas
on dynamic contrast-enhanced magnetic resonance imaging scans
using a histogram-based threshold. The orange-shaded regions indicate
enhancing areas while the remaining spinal cord tissue (excluding
cerebrospinal fluid) indicates non-enhancing tissue. This set of images was
taken from a 2 day post-SCI anatomical scan.
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After application of the SID-based threshold in a given slice, if enhancing
tissue areas was detected, then the corresponding normal-appearing tissue area
for that slice was defined as the difference between the total spinal cord area and
the enhancing areas. If no enhancing areas were detected in a slice, then the
normal-appearing area for that slice was the entire spinal cord area. Thus, it was
possible for a single slice of the spinal cord to simultaneously contain enhancing
and normal-appearing tissue areas. In each slice, gross BSCB compromise
(expressed as a percent) was defined as the ratio of the area of the enhancing ROI
to the area of the spinal cord cross-section. For reporting of gross BSCB
compromise by spatial region, the gross compromise for each slice in the region
was averaged.
The mathematical model for analyzing the DCE-MRI data in rat spinal cord
has been previously described (Bilgen and Narayana, 2001). For quantification of
Gd leakage through the compromised BSCB, a two-compartment model was
employed (Figure 2.6). One compartment represents the systemic circulation
(intravascular) and the second compartment represents the extravascular
extracellular space (EES) within the spinal cord. The adequacy of a twocompartment model in spinal cord has been demonstrated in (Bilgen et al., 2001;
Bilgen et al., 2002; Cohen et al., 2009; Patel et al., 2009). The concentration of Gd
in the spinal cord EES at each time point t, (Gd(t)EES), was estimated according to
the following equation (Cohen et al., 2009):
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Kps
[Gd]plasma

Ksp

[Gd]spinal
cord

Figure 2.6 – Two-compartment pharmacokinetic model of blood-spinal
cord barrier (BSCB) permeability. Kps is the parameter of interest for
describing extravasation of the Gd contrast agent from the systemic
vasculature (plasma compartment) to the extravascular extraspinal space
(spinal cord compartment), i.e. “leakiness” of the BSCB.

The parameter Kps represents the transfer rate of Gd from systemic circulation to
the EES of the spinal cord. The rate of influx of Gd from the systemic circulation
into the EES is Kps * [Gd(t)]Systemic Circulation. The values of Gd(t)EES at each time point
(based on DCE-MRI data) were fitted to the above equation using a nonlinear least
squares method in Matlab (MathWorks, Inc., Natick, MA) to estimate Kps. Because
of the uncertainty in the exact time of Gd injection and because it improved the
ability of the model to fit the data, the time of contrast injection (t0) was also
estimated as a part of the curve fitting routine.

MRI data analysis: RARE scans (lesion size)
For SCI lesion analysis, the second echo of the dual-echo RARE MRI
sequence provides important information about the pathological tissue changes
(e.g., hemorrhage and necrosis). Acutely after SCI, hypointense (dark) areas on

26

these images represent hemorrhage while hyperintense (bright) areas represent
edema (Weirich et al., 1990) (Figure 2.7). Hyperintense, hypointense, and total
(hyperintense + hypointense) lesion sizes were calculated for each slice in the
three spatial regions. Data were separately analyzed for hyperintense and
hypointense lesions. Unlike previous studies that have relied on hand-drawn
segmentation (Nout et al., 2009) or objective segmentation of these lesions based
on absolute pixel intensity thresholds (Sundberg, 2009; Qian et al., 2010), the
current studies employed a slice-by-slice objective technique based on the
probability density function (PDF) of pixel intensity in each slice (histogram-based
approach).

Dorsal
#

*

Ventral
Caudal

Epicenter

Rostral

Figure 2.7 – Example of hyperintense (#) and hypointense (*) tissue
areas on anatomical magnetic resonance imaging scans. During the
acute phase of spinal cord injury.

Images of the second echoes of the 35-slice RARE scan were exported
from Paravision software (Bruker Biospec, Karlsruhe, Germany) in analyze format.
The images were processed to reduce the field inhomogeneity using in-house
developed software (Hui et al., submitted). Using ImageJ software (NIH, Bethesda,
MD), a ROI encompassing the entire spinal cord but excluding peripheral CSF was
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drawn for each slice within the 13 slices under investigation (this represents a span
of 13 mm centered at the SCI epicenter). Next, the PDF of pixel intensity that
represents the normalized pixel intensity distribution (unit area under the curve)
was generated for each slice. Finally, the area of the SCI lesion as a fraction of the
spinal cord cross-sectional area was determined in an objective way. On a sliceby-slice basis, pixels whose intensity was less than or equal to µpixel intensity – n*σpixel
intensity

(µ represents mean and σ represents standard deviation of the mean) were

considered to compose the hypointense lesion and pixels whose intensity was
greater than or equal to µpixel intensity + n*σpixel intensity were considered to compose the
hyperintense lesion, n

 {1,

1.5, 2, 2.5, 3}. For example, assuming a normal

distribution, a threshold of n=2 represents an area under the curve of 2.28% at the
end of each tail, resulting in 95.4% of all pixels being rejected upon application of
the threshold. For each slice, the total lesion area was defined as the sum of the
hyperintense and hypointense lesion areas.
Because there is no gold standard for quantitating SCI lesion size on MRI
scans (most approaches employ human raters) and histological approaches tend
to overestimate lesion size (Ditor et al., 2008), the validity of the histogram-based
approach described above was evaluated using the majority voting rule on
segmentations of human raters. Four independent experienced raters segmented
(using ImageJ) the hyperintense and hypointense lesion from a random series of
16 anatomical MRI slices representing the heterogeneity of time points and spatial
regions under study. The raters were instructed to limit their segmentation to the
spinal cord parenchyma, excluding the bordering CSF. The raters were blinded to
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each other’s segmentations and were proctored by the same investigator, who did
not provide any guidance during the approximately 30-minute segmentation period.
The raters’ segmentations were individually saved using the ROI manager in
ImageJ and the hyperintense and hypointense lesion sizes in each slice were
calculated for each rater. For each slice, the reference image was defined on a
pixel-by-pixel basis, assigning a value of 1=yes when the majority of raters (>2)
assigned a value of 1=yes to that pixel. All other pixels in the reference image were
assigned a value of 0=no. Next, the histogram-based segmentation was applied to
the 16 rater-segmented slices,  n. The n-value of the histogram-based approach
that yielded the most comparable performance with rater-based hyperintense and
hypointense lesion sizes (based on measures including sensitivity and specificity)
was defined as the optimal histogram-based approach n-value. This n-value was
used for the quantification of hyperintense, hypointense, and total lesion area in
the Ang1 and vehicle groups.

MRI data analysis: DTI scans (axonal integrity)
All DTI data were analyzed using procedures described elsewhere (Madi et
al., 2005). In these studies, fractional anisotropy (FA) was targeted as the measure
of anisotropy because it is less susceptible to noise (Hasan et al., 2004). In order
to improve pathologic specificity for fiber tract integrity, transverse diffusivity (λT),
longitudinal diffusivity (λL), and mean diffusivity (MD) were also determined from
DTI data (Deo et al., 2006; Herrera et al., 2007). Decoding and diagonalization was
performed using in-house developed software (Hasan and Narayana, 2003) that
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was implemented under IDL 6.1 (ITT Visual Information Solutions, Boulder, CO).
DTI Studio (Department of Radiology, Johns Hopkins School of Medicine) was
used to calculate the value of the DTI measures within each ROI (e.g. dorsal white
matter [WM]). The specific WM ROIs are displayed in Figure 2.8. In addition to the
evaluation of DTI measures in the lateral, dorsal, and ventral WM ROIs (Deo et al.,
2006), a dorsal corticospinal tract (CST) ROI was also evaluated. The placement
of the ROIs in these areas, particularly the CST, facilitated longitudinal correlation
analysis between the DTI measures and measures from neurobehavioral assays.

Figure 2.8 - Pictorial of white matter regions of interest (ROIs) defined for
diffusion tensor imaging analysis. C = corticospinal tract, D = dorsal white
matter, L = lateral white matter, and V = ventral white matter.

Statistics
Data and statistical analysis was performed using Intercooled Stata version
9.2 (StataCorp LP, College Station, TX). At least 6 animals per treatment group per
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time point were included for analysis of all primary outcome measures, which
included:


BBB score, angle of maximum incline tolerated, footfalls (%), prevalence
of chronic pain, gross motor movement, fine motor movement, and
rearing activity from neurobehavioral assays (at time points indicated in
the “Neurobehavioral assessment” section of this chapter)



Kps metric (min-1) in enhancing and non-enhancing areas, and frank
contrast enhancement (%) from DCE-MRI scans (at 2, 7, 14, 28, 42, and
56 days post-SCI)



Hyperintense and hypointense lesion size (percent of spinal cord crosssectional area) and specificity/sensitivity of rater- and histogram-based
approaches for lesion segmentation from RARE MRI scans (at 2, 7, 14,
28, 42, and 56 days post-SCI)



FA, MD, λT, and λL values in white matter ROIs from DTI scans (at 7, 14,
28, 42, and 56 days post-SCI)

Statistical analyses were performed to determine (1) if, compared to vehicle,
administration of Ang1 acutely after SCI affected any of these parameters and (2)
whether there were any correlations between (a) BBB score and RARE and DTI
measures and between (b) RARE and DTI measures. Wilcoxon rank-sum analysis
was used to test for significant differences between treatment groups at each time
point.
For analysis of longitudinal data, the generalized estimating equation (GEE)
approach was used. The GEE technique has been widely used for the analysis of
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repeated measurement data due to flexibility in modeling nonuniform correlational
structures of repeated measurements and in handling the unequal number of
observations for each experimental unit. GEE was used to examine the pair-wise
association of MRI metrics and neurobehavioral measures.
All values are reported as mean ± standard error of the mean (SEM) unless
otherwise stated. Statistical significance was defined as α = 0.05, with corrections
for multiple comparisons based on the multiple spatial regions and time points
(Bonferroni adjustment).
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CHAPTER 3:

EFFECT OF SINGLE ACUTE ANG1 DOSE ON BLOOD-SPINAL CORD
BARRIER COMPROMISE AND PERMEABILITY
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INTRODUCTION
Following the primary mechanical damage from contusive injury to the
spinal cord, various secondary pathobiological processes ensue. The secondary
injury is the therapeutic target for improving long-term outcome. Compromise of
the BSCB is a secondary mechanism that plays an important role in SCI (Noble
and Maxwell, 1983; Noble and Wrathall, 1987, 1988, 1989; Popovich et al., 1996;
Tator and Koyanagi, 1997; Mautes et al., 2000; Pan et al., 2001; Bilgen et al.,
2002; Pan et al., 2003; Whetstone et al., 2003; Sharma, 2005; Maikos and
Shreiber, 2007; Pan and Kastin, 2008; Cohen et al., 2009). Studies investigating
the acute mitigation of BSCB breakdown have reported neuroprotective, antiinflammatory, and locomotor recovery benefits in SCI animal models (Sharma,
2000; Pan et al., 2001; Noble et al., 2002; Nyberg and Sharma, 2002; Kaptanoglu
et al., 2003; Sharma, 2003, 2006; Sharma et al., 2006a; Sharma et al., 2007).
However, some experimental therapies have required high doses that may be
inappropriate in human SCI patients due to harmful side effects.
Angiopoietin-1 is an essential protein (Suri et al., 1996) that plays a role in
vascular development and remodeling, specifically in the stabilization of blood
vessels (Hayes et al., 1999; Thurston et al., 1999; Thurston et al., 2000; Koh et al.,
2002; Uemura et al., 2002; Baffert et al., 2006), via activation of the Tie-2 receptor
tyrosine kinase expressed on endothelial cells (Davis et al., 1996). Ang1’s effects
have been studied in vitro, suggesting mechanisms of action that include increased
endothelial cell survival (Papapetropoulos et al., 2000; Harfouche et al., 2002;
Tadros et al., 2003), reduced inflammation (Hughes et al., 2003; Imhof and
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Aurrand-Lions, 2006), upregulation of tight junction proteins (Iizasa et al., 2002;
Hori et al., 2004; Wang et al., 2007), and neuroprotection (Valable et al., 2003).
Ang1 is thought to have therapeutic potential in reducing blood-brain barrier
breakdown after brain injury (Nourhaghighi et al., 2003) and has been shown to
reduce vascular permeability in experimental models of CNS vascular disease
(Zhang et al., 2002; Valable et al., 2005; Ohab et al., 2006; Chen et al., 2008;
Childs et al., 2008; Cui et al., 2008a; Cui et al., 2008b; Onda et al., 2008).
Recently, daily administration of Ang1 post-SCI was shown to reduce vascular
permeability and CD3-positive T cell infiltration after experimental SCI in a mouse
model (Han et al., 2010). Compared to other therapies that may reduce BSCB
permeability, Ang1 has been shown to be tolerated at high circulating levels
(Thurston et al., 2000).
Dynamic contrast-enhanced MRI is a powerful noninvasive technique for
quantifying BSCB permeability in vivo in SCI (Runge et al., 1997; Bilgen et al.,
2001; Bilgen and Narayana, 2001; Cohen et al., 2009; Patel et al., 2009). In DCEMRI, T1-weighted magnetic resonance images are serially acquired following
intravenous administration of paramagnetic contrast agents such as gadodiamide
(Gd, molecular weight (MW) = 0.573 kDa) (Tofts et al., 1999). In the absence of
SCI, the intact BSCB strictly regulates entry of molecules from the systemic
vasculature into the spinal cord. However, when the BSCB is compromised due to
SCI, these molecules leak out from the vasculature into the spinal cord
parenchyma (Baldwin et al., 1998). When a contrast agent (e.g., Gd) extravasates

35

into the injured spinal cord via the compromised BSCB, it renders the surrounding
tissue area hyperintense on T1-weighted MRI scans.
In the acute phase of SCI, frank enhancement of tissue is observed due the
mechanical trauma-induced BSCB disruption in the epicenter region (Bilgen et al.,
2001) and spreads to the adjacent regions (Bilgen et al., 2000). However, recent
studies have demonstrated that the so-called “normal appearing” non-enhancing
tissue areas, those with no visual contrast enhancement, also exhibit compromised
BSCB (Kobiler et al., 2001; Cohen et al., 2009; Patel et al., 2009). Using an
appropriate pharmacokinetic model (Bilgen and Narayana, 2001), the temporal
changes in the contrast agent-induced signal increase observed with DCE-MRI
can be quantitatively related to the BSCB permeability (Bilgen et al., 2001; Bilgen
and Narayana, 2001; Bilgen et al., 2002; Bilgen et al., 2007; Cohen et al., 2009;
Patel et al., 2009).
In the present studies we used DCE-MRI to investigate the effects of a
single dose of Ang1 (administered intraspinally immediately after experimental
SCI) on the temporal and spatial evolution of frank BSCB compromise and BSCB
permeability. For each time point assessed (days 2, 7, 14, 28, 42, and 56 postSCI), at least 6 animals were studied in each group.

36

RESULTS
Frank enhancement (absolute area)
Frank enhancement on DCE-MRI scans is a result of gross BSCB
compromise. Figure 3.1 displays the frank enhancement in absolute area (mm2,
defined as the area of spinal cord tissue with contrast-enhancement on DCE-MRI
scans above the 35% threshold) by day and spatial region, while Figure 3.2
displays the data longitudinally. Compared to vehicle, Ang1 treatment resulted in a
significant increase in frank enhancement in the caudal region at day 14 post-SCI,
while it resulted in a significant decrease in the epicenter region at days 2, 28, and
42 post-SCI, and in the rostral region at days 2, 28, and 42 post-SCI.
Figure 3.3 displays the data by time period. Compared to vehicle, Ang1
treatment resulted in a significant decrease in frank enhancement (absolute area)
in the acute phase (epicenter and rostral regions), subacute phase (caudal and
rostral regions), and chronic phase (epicenter and rostral regions).
Table 3.1 summarizes, for each group, the significant spatial and temporal
differences in frank enhancement after SCI. In all three regions and in each group,
there was a significant reduction at days 42 and 56 compared to day 2 post-SCI,
indicating reduced frank enhancement over time in both groups. In the caudal
region, there was a significant decrease from day 28 post-SCI to day 42 post-SCI
in both groups, with a further reduction at day 56 post-SCI in the Ang1 group only,
indicating continued restoration of the BSCB in this region. At all time points in both
groups, the epicenter region contained significantly greater frank enhancement
than the adjacent caudal and/or rostral region. In addition, the rostral region
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contained significantly greater frank enhancement compared to the caudal region
in the chronic phase, indicating a spatial asymmetry in restoration of the BSCB
after SCI.
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Figure 3.1 - Frank enhancement (absolute area, mm2) by day and spatial
region. Error bars represent standard error of the mean. * indicates p<0.0167
between vehicle and Ang1. n≥6 animals per group per day.
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Figure 3.2 - Frank enhancement (absolute area, mm2) by day and spatial
region (temporal view). Error bars represent standard error of the mean. *
indicates p<0.0167 between vehicle and Ang1. n≥6 animals per group per
day.
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Figure 3.3 - Frank enhancement (absolute area, mm2) by phase of injury
and spatial region (including temporal view). Error bars represent standard
error of the mean. * indicates p<0.0167 between vehicle and Ang1. n≥6 animals
per group per phase.
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Temporal comparisons of frank enhancement (absolute area), by region
Group
Caudal Region
Epicenter Region
Rostral Region
d2 > d{14, 28, 42, 56}
d2 > d{7, 14, 28, 42, 56} d2 > d{14, 28, 42, 56}
d7 > d{28, 42, 56}
d7 > d{28, 42, 56}
d7 > d{14, 42, 56}
d14 > d{42, 56}
Vehicle
d28 > d42
d28 > d56
pA > {pS, pC}
pA > {pS, pC}
pA > {pS, pC}
pS > pC
pS > pC
pS > pC
d2 > d{28, 42, 56}
d2 > d{14, 28, 42, 56}
d2 > d{42, 56}
d7 > d{42, 56}
d7 > d{14, 28, 42, 56}
d14 > d{42, 56}
Angiopoietin-1
d28 > d{42, 56}
pA > {pS, pC}
pA > {pS, pC}
pA > {pS, pC}
pS > pC
pS > pC
Spatial comparisons of frank enhancement (absolute area), by days post-SCI
Group
d2
d7
d14
d28
d42
d56
rE > r{C, R} rE > r{C, R} rE > rR
rE > r{C, R} rE > r{C, R} rE > rC
Vehicle
rR > rC
rE > r{C, R} rE > r{C, R} rE > r{C, R} rE > r{C, R} rE > r{C, R} rE > rC
Angiopoietin-1
rR > rC
Spatial comparisons of frank enhancement (absolute area), by phase of SCI
Group
Acute Phase
Subacute Phase
Chronic Phase
rE > r{C, R}
rE > r{C, R}
rE > r{C, R}
Vehicle
rR > rC
rE > r{C, R}
rE > r{C, R}
rE > r{C, R}
Angiopoietin-1
rR > rC
Table 3.1 - Spatial and temporal differences in frank enhancement (absolute area) after
spinal cord injury (SCI). Only significant differences shown (p<0.0033 for inter-day comparisons
in a given spatial region; p<0.0167 for inter-phase comparisons in a given spatial region; p<0.0167
for spatial region comparisons on a given day post-SCI or phase of injury). d = days post-SCI, pA =
acute phase, pC = chronic phase, pS = subacute phase, rC = caudal region, rE = epicenter region,
rR = rostral region. n≥6 animals per group per day (or phase).
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Frank enhancement (relative area)
Because the spinal cord cross-sectional area may change after SCI (e.g.,
due to atrophy (Deng et al., 2007)), we normalized the frank enhancement
(absolute area) as frank enhancement (relative area). The latter parameter was
defined for each slice as the area of spinal cord tissue with contrast-enhancement
on DCE-MRI scans (i.e., above the 35% threshold) divided by the spinal cord cross
sectional area. These results are shown in Figure 3.4, by day and spatial region.
Figure 3.5 displays this data longitudinally. Compared to vehicle, Ang1 treatment
resulted in a significant decrease in frank enhancement in the caudal region at day
2 post-SCI, in the epicenter region at days 2, 28, and 42 post-SCI, and in the
rostral region at days 2, 7, and 42 post-SCI.
Figure 3.6 displays the data by time period. Compared to vehicle, Ang1
treatment resulted in a significant decrease in frank enhancement (relative area) in
the acute phase (all three regions), subacute phase (caudal and rostral regions),
and chronic phase (epicenter and rostral regions).
Table 3.2 summarizes, for each group, the significant spatial and temporal
differences in frank enhancement after SCI. In all three regions and in each group,
there was a significant reduction at days 42 and 56 compared to day 2 post-SCI,
indicating reduced frank enhancement over time in both groups. In the caudal
region, there was a significant decrease from day 28 post-SCI to day 42 post-SCI
in both groups, with a further reduction at day 56 post-SCI in the Ang1 group only,
indicating continued restoration of the BSCB in this region. At all time points in both
groups, the epicenter region contained significantly greater frank enhancement
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than the adjacent caudal and/or rostral region. In addition, the rostral region
contained significantly greater frank enhancement compared to the caudal region
in the chronic phase, indicating a spatial asymmetry in restoration of the BSCB
after SCI.
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Figure 3.4 - Frank enhancement (relative area, percent) by day and spatial
region. Error bars represent standard error of the mean. * indicates p<0.0167
between vehicle and Ang1. n≥6 animals per group per day.
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between vehicle and Ang1. n≥6 animals per group per day.
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Figure 3.6 - Frank enhancement (relative area, percent) by phase of
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n≥6 animals per group per phase.
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Temporal comparisons of frank enhancement (relative area), by region
Group
Caudal Region
Epicenter Region
Rostral Region
d2 > d{14, 28, 42, 56}
d2 > d{7, 14, 28, 42, 56} d2 > d{14, 28, 42, 56}
d7 > d{28, 42, 56}
d7 > d{28, 42, 56}
d7 > d{14, 56}
d14 > d{42, 56}
Vehicle
d28 > d42
d28 > d56
d28 > d56
pA > p{S, C}
pA > p{S, C}
pA > p{S, C}
pS > pC
pS > pC
pS > pC
d2 > d{42, 56}
d2 > d{14, 28, 42, 56}
d2 > d{42, 56}
d7 > d{42, 56}
d7 > d{14, 28, 42, 56}
d14 > d{42, 56}
d14 > d56
Angiopoietin-1
d28 > d{42, 56}
pA > pC
pA > pC
pA > pC
pS > pC
pS > pC
Spatial comparisons of frank enhancement (relative area), by days post-SCI
Group
d2
d7
d14
d28
d42
d56
rE > r{C, R} rE > r{C, R} rE > r{C, R} rE > r{C, R} rE > r{C, R} rE > rC
Vehicle
rC < rR
rE > r{C, R} rE > r{C, R} rE > r{C, R} rE > r{C, R} rE > r{C, R} rE > rC
Angiopoietin-1
rC < rR
Spatial comparisons of frank enhancement (relative area), by phase of SCI
Group
Acute Phase
Subacute Phase
Chronic Phase
rE > r{C, R}
rE > r{C, R}
rE > r{C, R}
Vehicle
rC < rR
rE > r{C, R}
rE > r{C, R}
rE > r{C, R}
Angiopoietin-1
rC < rR
Table 3.2 - Spatial and temporal differences in frank enhancement (relative area) after spinal
cord injury (SCI). Only significant differences shown (p<0.0033 for inter-day comparisons in a
given spatial region; p<0.0167 for inter-phase comparisons in a given spatial region; p<0.0167 for
spatial region comparisons on a given day post-SCI or phase of injury). d = days post-SCI, pA =
acute phase, pC = chronic phase, pS = subacute phase, rC = caudal region, rE = epicenter region,
rR = rostral region. n≥6 animals per group per day (or phase).
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BSCB permeability in tissue areas exhibiting contrast enhancement
Next,

the

established

two-compartment

pharmacokinetic

model

for

determination of BSCB permeability (defined as Kps, the rate constant of leakage
from the systemic vasculature into the extravascular extracellular space of the
spinal cord) was employed. Figure 3.7 displays the BSCB permeability in spinal
cord tissue exhibiting contrast-enhancement (Kps-enhancing) on DCE-MRI scans
(i.e., above the 35% threshold), by day and spatial region, while Figure 3.8
displays the data longitudinally. There was no inter-group difference in Kpsenhancing at any day post-SCI or in any region, indicating that the permeability in
tissue areas with compromised BSCB was not affected by Ang1. Figure 3.9
displays the data by time period. Again, the effects of Ang1 on the permeability of
tissue with compromised BSCB were indistinguishable from those of vehicle, for all
regions and time periods.
Table 3.3 summarizes, for each group, the significant spatial and temporal
differences in Kps-enhancing after SCI. In the vehicle-treated animals, there was a
significant reduction at day 14 post-SCI compared to day 2 post-SCI and in the
subacute phase compared to the acute phase (epicenter region) and a significant
increase in the chronic phase compared to the subacute phase (rostral region). In
addition to these differences, others were identified in the Ang1-treated animals: a
significant reduction at day 7 post-SCI compared to day 2 post-SCI and in the
subacute phase compared to the acute phase (caudal region), a significant
reduction at day 7 post-SCI compared to day 2 post-SCI and a significant increase
in the chronic phase compared to the subacute phase (epicenter region), and a
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significant reduction in the subacute phase compared to the acute phase (rostral
region). These findings reflect the effect of Ang1 on reducing Kps-enhancing during
the acute and subacute phases, to an extent greater than that of vehicle. In both
groups the significant increase in the chronic phase compared to the subacute
phase in the rostral region (a reversal of the significant difference between the
acute and subacute phases) without a concomitant increase in the caudal region
during the same time frame further suggests a spatial asymmetry that was
detectable during the chronic phase of SCI.

48

0.1

Vehicle
Ang1
0.05

Kps (1/min)

Kps (1/min)

0.1

Enhancing Area BSCB
Permeability (28 d)

Enhancing Area BSCB
Permeability (2 d)

0

Vehicle
Ang1
0.05

0

Caudal

Epicenter

Rostral

Caudal

0.1

Vehicle
Ang1
0.05

Vehicle
Ang1
0.05

0

0

Caudal

Epicenter

Rostral

Caudal

Epicenter

Rostral

Region

Region

Enhancing Area BSCB
Permeability (14 d)

Enhancing Area BSCB
Permeability (56 d)

0.1

0.4

Vehicle
Ang1
0.05

0

Kps (1/min)

Kps (1/min)

Rostral

Enhancing Area BSCB
Permeability (42 d)

Enhancing Area BSCB
Permeability (7 d)
Kps (1/min)

Kps (1/min)

0.1

Epicenter

Region

Region

Vehicle
Ang1

0.3
0.2
0.1
0

Caudal

Epicenter

Region

Rostral

Caudal

Epicenter

Rostral

Region

Figure 3.7 - Blood-spinal cord barrier (BSCB) permeability in spinal cord
tissue areas exhibiting contrast enhancement, by day and spatial region.
Kps indicates the permeability/leakiness of the BSCB. Error bars represent
standard error of the mean. n≥6 animals per group per day.
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Figure 3.8 - Blood-spinal cord barrier (BSCB) permeability in spinal cord
tissue areas exhibiting contrast enhancement, by day and spatial region
(temporal view). Kps indicates the permeability/leakiness of the BSCB. Error
bars represent standard error of the mean. n≥6 animals per group per day.
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Figure 3.9 - Blood-spinal cord barrier (BSCB) permeability in spinal cord
tissue areas exhibiting contrast enhancement, by phase of injury and
spatial region (including temporal view). Kps indicates the
permeability/leakiness of the BSCB. Error bars represent standard error of the
mean. n≥6 animals per group per phase.
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Temporal comparisons of BSCB permeability (enhancing tissue areas), by region
Group
Caudal Region
Epicenter Region
Rostral Region
d2 > d14
Vehicle
pA > pS
pS < pC
d2 > d7
d2 > d{7, 14}
Angiopoietin-1
pA > pS
pA > pS
pA > pS
pS < pC
pS < pC
Spatial comparisons of BSCB permeability (enhancing tissue areas), by days post-SCI
Group
d2
d7
d14
d28
d42
d56
Vehicle
rE > r{C, R}
Angiopoietin-1
rC < rE
rC < rE
Spatial comparisons of BSCB permeability (enhancing tissue areas), by phase of SCI
Group
Acute Phase
Subacute Phase
Chronic Phase
Vehicle
rE > r{C, R}
Angiopoietin-1
rC < rE
rC < rE
Table 3.3 - Spatial and temporal differences in blood-spinal cord barrier (BSCB)
permeability in enhancing tissue areas after spinal cord injury (SCI). Only significant
differences shown (p<0.0033 for inter-day comparisons in a given spatial region; p<0.0167 for
inter-phase comparisons in a given spatial region; p<0.0167 for spatial region comparisons on a
given day post-SCI or phase of injury). d = days post-SCI, pA = acute phase, pC = chronic phase,
pS = subacute phase, rC = caudal region, rE = epicenter region, rR = rostral region. n≥6 animals
per group per day (or phase).

BSCB permeability in “normal appearing” tissue areas that do not exhibit
contrast enhancement
Three uninjured animals underwent DCE-MRI scans 7 days after
implantation of the radiofrequency coil and vascular port, to allow enough time for
them to recover. Based on the analysis of data from these scans, the value for
baseline BSCB permeability (Kps-uninjured) was determined to be 0.00759±0.0007
min-1.
In regards to the SCI animals, Figure 3.10 displays Kps-normal-appearing by
day and spatial region, while Figure 3.11 displays the data longitudinally.
Compared to vehicle, Ang1 treatment resulted in significantly decreased Kpsnormal-appearing at day 2 post-SCI (in all three regions), day 7 post-SCI (in the
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rostral region), day 28 post-SCI (in the epicenter region), and day 42 post-SCI (in
the rostral region).
Figure 3.12 displays the data by time period. There was a significant
reduction in Kps-normal-appearing in the Ang1 group compared to the vehicle
group during the acute (in all three regions), subacute (in the rostral region), and
chronic (in the epicenter region) phases.
Table 3.4 displays, for each group, the significant spatial and temporal
differences in Kps-normal-appearing after SCI. In the caudal region, Kps-normalappearing was significantly reduced in the subacute phase (vehicle group) and
chronic phase (Ang1 group) compared to in the acute phase, indicating its delayed
reduction in the Ang1 group in this region. In the epicenter and rostral regions, Kpsnormal-appearing was significantly reduced in both the subacute and chronic
phases in both groups. Treatment with Ang1 delayed the reduction of Kps-normalappearing after the acute phase in the caudal region compared to the rostral
region, while treatment with vehicle did not maintain the reduced Kps-normalappearing in the caudal region after the subacute phase. In the acute phase, Kpsnormal-appearing was significantly reduced in the caudal (but not rostral) region
compared to the epicenter region in both groups. In the subacute phase, Kpsnormal-appearing was significantly reduced in the rostral (but not caudal) region in
the Ang1 group only. In the chronic phase, Kps-normal-appearing was significantly
reduced in both the caudal and rostral regions compared to the epicenter region in
the Ang1 group only. This, coupled with the findings of Figure 3.2, could suggest
that as the effects of Ang1 extend spatially with increasing time post-SCI (i.e., in
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the chronic phase), the effect of reduced perilesional Kps-normal-appearing is
pronounced.
Table 3.5 summarizes the phenomenon of persistent elevated BSCB
permeability in normal-appearing tissue. Compared to the value of Kps-normalappearing in uninjured animals, the value of Kps-normal-appearing in both groups
was significantly increased in all three regions during all three phases of injury,
with one exception: in the Ang1 group rostral region during the subacute phase
(p<0.06).
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Figure 3.10 - Blood-spinal cord barrier (BSCB) permeability in nonenhancing spinal cord tissue areas, by day and spatial region. Kps indicates
the permeability/leakiness of the BSCB. Error bars represent standard error of
the mean. * indicates p<0.0167 between vehicle and Ang1. n≥6 animals per
group per day.
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Figure 3.11 - Blood-spinal cord barrier (BSCB) permeability in nonenhancing spinal cord tissue areas, by day and spatial region
(temporal view). Kps indicates the permeability/leakiness of the BSCB.
Error bars represent standard error of the mean. Uninj = uninjured. *
indicates p<0.0167 between vehicle and Ang1. n≥6 animals per group per
day.
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Figure 3.12 - Blood-spinal cord barrier (BSCB) permeability in nonenhancing spinal cord tissue areas, by phase of injury and spatial region
(including temporal view). Kps indicates the permeability/leakiness of the
BSCB. Error bars represent standard error of the mean. * indicates p<0.0167
between vehicle and Ang1. n≥6 animals per group per phase.
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Temporal comparisons of BSCB permeability (non-enhancing tissue areas), by region
Group
Caudal Region
Epicenter Region
Rostral Region
d2 > d{14, 56}
d2 > d{7, 14, 28, 42}
d2 > d{14, 28}
Vehicle
d7 > d14
pA > pS
pA > p{S, C}
pA > {S, C}
d2 > d{14, 42}
d2 > d{7, 14, 28, 42, 56} d2 > d{7, 14, 28, 42, 56}
Angiopoietin-1
d7 > d14
pA > pC
pA > p{S, C}
pA > p{S,C}
Spatial comparisons of BSCB permeability (non-enhancing tissue areas), by days post-SCI
Group
d2
d7
d14
d28
d42
d56
Vehicle
rC < rE
rC < rE
rC < rE
Angiopoietin-1
rC < rE
rE > rR
Spatial comparisons of BSCB permeability (non-enhancing tissue areas), by phase of SCI
Group
Acute Phase
Subacute Phase
Chronic Phase
Vehicle
rC < rE
Angiopoietin-1
rC < rE
rE > rR
rE > r{C, R}
Table 3.4 - Spatial and temporal differences in blood-spinal cord barrier (BSCB)
permeability in non-enhancing tissue areas after spinal cord injury (SCI). Only significant
differences shown (p<0.0033 for inter-day comparisons in a given spatial region; p<0.0167 for
inter-phase comparisons in a given spatial region; p<0.0167 for spatial region comparisons on a
given day post-SCI or phase of injury). d = days post-SCI, pA = acute phase, pC = chronic phase,
pS = subacute phase, rC = caudal region, rE = epicenter region, rR = rostral region. n≥6 animals
per group per day (or phase).

Days post-SCI
Phase of injury
2
7
14 28 42 56 Acute Subacute Chronic
Caudal
+
+
+
+
+
+
Vehicle Epicenter +
+
+
+
+
+
+
+
Rostral
+
+
+
+
+
Caudal
+
+
+
+
+
Ang1 Epicenter +
+
+
+
+
+
+
+
Rostral
+
+
+
+
Table 3.5 - Evaluating persistently increased blood-spinal cord barrier
(BSCB) permeability in normal-appearing tissue after spinal cord injury
(SCI). Ang1 = angiopoietin-1. + indicates that the BSCB permeability for the
post-SCI temporal-region combination was greater than the BSCB permeability
in uninjured animals (p<0.0167).
Group Region
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DISCUSSION
Although not a causal relationship, we have previously identified a
significant correlation between decreased BSCB permeability in normal-appearing
areas and improved locomotor scores in experimental SCI (Cohen et al., 2009).
Decreasing the BSCB permeability acutely after SCI may mitigate the severity of
extravascular secondary pathologies. Using spatiotemporal analysis, the primary
aim of these studies was to determine if a single dose of Ang1 delivered by
microinjection directly into the lesion immediately post-SCI would result in reduced
BSCB compromise and permeability.

Frank Enhancement
Due to the variability of spinal cord tissue preservation and atrophy after
injury (Weirich et al., 1990; Deng et al., 2007), normalization of the area of tissue
exhibiting contrast enhancement to the total cross-sectional area provided for
meaningful comparisons between the groups. Although this is approach is semiquantitative, it has been shown to be correlated with quantitative analysis in a
human study (Galbraith et al., 2002). The reduction in frank enhancement
attributable to Ang1 began at 2 days post-SCI and lasted up to 42 days post-SCI in
the epicenter and rostral regions, but was limited at 2 days post-SCI in the caudal
region. Yet in the caudal region, a significant reduction in frank enhancement from
day 28 post-SCI to day 56 in the Ang1 group (but only to day 42 in the vehicle
group)

may indicate prolonged restoration of the BSCB in this region after

exposure to Ang1. This complements the finding that in both groups during the
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chronic phase, frank enhancement was significantly greater in the rostral region
compared to the caudal region.

BSCB permeability in tissue areas exhibiting contrast enhancement
Given that tissues with contrast-enhancement reflect extravasation of the
contrast agent from the systemic vasculature through the compromised BSCB into
the spinal cord, we did not expect to detect inter-group differences in Kpsenhancing. Indeed, this was the case and it confirmed our previous findings of no
differences in Kps-enhancing after experimental SCI with a different vehicle (saline)
and experimental treatment (vascular endothelial growth factor) (Patel et al., 2009).
Although Kps-enhancing was significantly decreased in the caudal region compared
to the epicenter region in both groups during the acute phase, this difference was
extended into the subacute phase in the Ang1 group only, indicating a possible
effect of Ang1 in mediating the delay of normalization of Kps-enhancing between
these two regions (i.e., loss of significant difference) during this phase of injury.

BSCB permeability in “normal appearing” tissue areas that do not exhibit
contrast enhancement
The value of Kps-uninjured in this study (0.00759±0.0007 min-1) is
comparable to that previously reported as a baseline value (0.00698 ± 0.0019 min1

) (Cohen et al., 2009), indicating the reliability of the two-compartment

pharmacokinetic model employed. Compared to vehicle, Ang1 resulted in a
significant reduction in Kps-normal-appearing in all three regions during the acute
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phase; however, the reduction was maintained only in the rostral region during the
subacute phase and in the epicenter region during the chronic phase. In a different
murine model of SCI (T9 contusion in mouse), Han et al. administered Ang1 daily
starting with the day of injury (with a delay of 4 hours between SCI and first Ang1
dose) (Han et al., 2010). They evaluated BSCB permeability histologically by
injecting luciferase 30 min prior to sacrifice and then quantifying the amount that
extravasated into the spinal cord at 24 hours and 72 hours post-SCI. Compared to
vehicle, they detected a significant reduction in BSCB permeability due to Ang1 in
the epicenter region (the same as the epicenter region defined in the current study,
5 mm centered about the lesion site) at 72 hours, but not 24 hours, post-SCI (Han
et al., 2010). Our findings at 2 days pos-SCI confirm Han et al.’s findings and
provide evidence for an effect of Ang1 that extends farther, up to 6 mm rostral and
6mm caudal to the site of injury. Furthermore, our data show that a single injection
of Ang1 administered immediately after SCI can reduced BSCB permeability in the
chronic phase of injury (28-56 days post-SCI), specifically up to 42 days post-SCI.
We have previously shown that “normal appearing” areas on post-contrast
DCE-MRI scans, i.e. those tissue areas that do not exhibit contrast enhancement,
undergo dynamic changes in BSCB permeability (Cohen et al., 2009; Patel et al.,
2009). In the current study we found that BSCB permeability in normal-appearing
areas was elevated compared to uninjured Kps-normal-appearing values in both
groups, in all three regions, in all three phases, with one exception: the Ang1 group
in the rostral region during the subacute phase. This was due to the fact that Kpsnormal-appearing was significantly reduced in the subacute phase in rostral region
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compared to the epicenter region in the Ang1 group only. Most previous studies of
BSCB permeability in SCI have employed ex vivo histological methods using
macromolecular tracers (e.g., albumin (Noble and Maxwell, 1983; Sharma et al.,
1998; Pan and Kastin, 2001; Sharma et al., 2006b), IgG (Baldwin et al., 1998), and
horseradish peroxidase (Noble and Maxwell, 1983; Noble and Wrathall, 1987,
1988, 1989)) whose sizes range from 40-150 kDa. An advantage of in vivo DCEMRI investigations is the ability to spatiotemporally evaluate changes in BSCB
compromise in the same cohort of animals at serial time points. As with in vivo
studies, post-mortem studies are susceptible to altered tissue microstructure. For
example, Popovich et al. found that the BSCB is compromised for as long as 28
days post-SCI and is completely restored thereafter (tracer:

14

C-labeled α-

aminoisobutyric acid, MW = 0.117 kDa) (Popovich et al., 1996) while Whetstone et
al. observed restoration of the BSCB between 7-14 days post-SCI (tracer:
luciferase, MW = 61 kDa) (Whetstone et al., 2003).
Contrary to the findings of Popovich et al. (Popovich et al., 1996) and
Whetstone et al. (Whetstone et al., 2003), based on DCE-MRI studies we have
found that the BSCB remains compromised even at 56 days post-SCI (Cohen et
al., 2009; Patel et al., 2009). This may be due to the size of the contrast agent
used in the DCE-MRI studies (Gd, molecular weight = 0.573 kDa) (Tofts et al.,
1999), which due to its small size would be expected to leak into epicenter and
perilesional regions during times when the BSCB has been restored to the point of
prohibiting larger molecules, i.e. during the chronic phase of injury. Interestingly,
Popovich et al. used a tracer smaller than Gd yet concluded restoration of the
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BSCB to be one month earlier than what we have determined; this highlights the
different conclusions that may be drawn from post-mortem versus in vivo studies,
respectively, even when comparably small tracers are used to probe the integrity of
the BSCB. Future DCE-MRI studies may determine that BSCB permeability to Gd
in normal-appearing tissue persists in the ultrachronic (>2 months post-SCI) phase
of injury. In regards to method of treatment delivery, we postulate that repeated
administration of Ang1 may result in a more potent and longer-lasting reduction in
BSCB compromise compared the effects observed in this study. Such
administration could take the form of daily injections of Ang1 protein administered
intravenously through the same vascular port used to administer the contrast agent
during DCE-MRI scans. Alternatively, sustained-release methods such as genebased delivery (Abdellatif et al., 2006) or mini-pump implantation could be
considered (Lee et al., 1999). In the former, administration of the agent in some
other form during the acute phase of injury may be necessary to compensate for
the delay (on the order of days (Boulis et al., 1999)) in the commencement of gene
expression, while in the latter, catheter patency, cord compression, and scarring
may hinder successful therapy long-term (Jones and Tuszynski, 2001).

Strengths
This study provides proof of principle that Ang1 reduces BSCB compromise
after experimental SCI, both in terms of the amount of tissue containing frank
enhancement and the permeability of the barrier. Despite a single administration of
Ang1 protein at the injury epicenter, differences compared to vehicle were
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observed in the perilesional area and at subacute and chronic time points. Further
evidence for the caudal-rostral asymmetry post-SCI was also demonstrated. The
persistently elevated BSCB permeability observed at all time periods and in all
regions in the vehicle group confirms our earlier findings in untreated SCI animals
(Cohen et al., 2009) and supports further investigation into delayed treatments for
spinal cord injury (Novikova et al., 2000; Lynskey et al., 2006; Hejcl et al., 2008),
many of which

are delivered intravenously and therefore must cross the

compromised BSCB in order to exert their effects (Wrathall et al., 1997; Huang et
al., 2007; Mann et al., 2008; Fleming et al., 2009).

Limitations
The results of this study should be considered in the context of its
limitations. First, a rigorous analysis of the distribution of the treatment (neither
vehicle nor Ang1) after spinal microinjection was not performed. Second, the
treatments were delivered intraspinally immediately after SCI, a scenario that is not
clinically translatable due to the delay involved in transit from site of injury to
tertiary care center and relative inaccessibility to the spinal cord unless surgical
decompression is warranted. Third, histological assessment was not performed as
part of this study, which could have validated the DCE-MRI results and provided
possible clues into the mechanism of action underlying the observed effects.
Fourth, the optimal dose and administration regimen of Ang1 is unknown because
a dose-response assessment was not performed.
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CHAPTER 4:

EFFECT OF SINGLE ACUTE ANG1 DOSE ON SPINAL CORD ATROPHY AND
SCI LESION SIZE

65

INTRODUCTION
Sparing of tissue has been shown to be associated with improved
neuromotor recovery after spinal cord injury (Noble and Wrathall, 1985; Behrmann
et al., 1992; Basso, 2000). The growing lesion after spinal cord injury spreads to
gray matter and white matter, hindering recovery (Nishi et al., 2007). T2-weighted
anatomical MRI can identify hyperintense (bright) and hypointense (dark) lesions
that correlate with pathology (Weirich et al., 1990). In the acute phase of injury,
hyperintense lesions represent edema and hypointense lesions represent
hemorrhage, while in the chronic phase of injury, hyperintense lesions represent
demyelination and hypointense lesions represent necrosis.
The traditional histological approach (i.e., method of Cavalieri) employed to
measure the lesion after spinal cord injury has been shown to be an overestimate
relative to that determined from MRI (Ditor et al., 2008). Even with MRI-based
visualization of the spinal cord in vivo, lesion analysis of MR images involves the
application of user-defined absolute thresholds for identifying hyper- and hypointense lesions (Nout et al., 2009; Sundberg, 2009; Qian et al., 2010).
The quantification of lesion size is further complicated by atrophy of the
spinal cord parenchyma over time (Olby and Blakemore, 1996; Deng et al., 2007).
High-resolution anatomical MR imaging has previously been used to quantify the
extent of atrophy. (Deng et al., 2007). In order to remove the confounder of atrophy
from reporting of lesion size, it may be appropriate to normalize the size of the
lesion by the cross-sectional area of the parenchyma on a slice-by-slice manner.
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The purpose of these studies was to evaluate the role of acutely
administered Ang1 on atrophy and lesion size after traumatic SCI. An objective
histogram-based method for lesion segmentation that can be easily implemented
in freeware software (ImageJ, Bethesda, MD) is described and evaluated against
segmentations from human raters.
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RESULTS
Rater-based segmentation
Sixteen high-resolution anatomical MRI slices were randomly chosen for
rater-based segmentation and representative images are shown in Figure 4.1 The
slices were derived from a cross-section of anatomical regions (caudal, epicenter,
and rostral) and time points (acute, subacute, and chronic phase). During the acute
phase of injury, hyperintense (bright) areas are representative of edema and
hypointense (dark) areas are representative of hemorrhage. In the late subacute
and chronic phases, the hyperintense areas represent demyelination and the
hypointense regions indicate necrosis (Weirich et al., 1990).

Caudal region

Epicenter region

Rostral region

Acute phase

Subacute phase

Chronic phase
Figure 4.1 – Representative sample of anatomical images segmented by
human raters. This set of images represents the heterogeneity hyperintense
and hypointense lesions seen over time and space. From a total of 16
images. Orientation: ventral on top, dorsal on bottom.

Four experienced raters with >1 year of experience assessing and
analyzing high-resolution anatomical MRI scans segmented the hyperintense and
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hypointense lesions from the set of 16. An example of the segmentation of the four
raters for a single slice is shown in Figure 4.2.

Figure 4.2 Rater segmentation (four raters) in a slice containing both
hyperintense and hypointense lesion. The numbers in each pixel refer to the
number of raters that classified the pixel as hyperintense or hypointense. Upper
left: high-resolution image, upper right: zoomed-in view, lower left: raters’
segmentation of hyperintense (bright) lesion, lower right: raters’ segmentation of
hypointense (dark) lesion.

For each slice, the “truth” or reference image was defined by the majority voting
rule, i.e. a pixel was considered to be part of lesion if more than two raters
classified it as containing lesion. In the event of a tie (i.e. 2 raters with the same
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classification), the pixel was not considered to be part of the lesion. The
segmentations from the histogram-based method (described in the Materials and
Methods chapter), as well as those from the human raters, were evaluated against
the reference image for each slice. The segmentation of a particular pixel was
considered to be a true positive (TP, if both the segmented and reference images
agreed that it belongs to a lesion), false positive (FP, if the segmented image
determined that the pixel belongs to a lesion, but the reference image did not), true
negative (TN, if the both the segmented and reference images determined that the
pixel is not part of the lesion), or false negative (FN, if the segmented image
determined that a pixel belongs to a lesion, but the reference image did).

Evaluation of objective histogram-based approach for lesion segmentation
Because the slices represented a heterogeneous cross-section of pathology
seen over the course of the study, evaluation of the performance of the human
raters and histogram-based method is presented by spatial region. Performance
measures included sensitivity (TP / [TP + FN], see Figure 4.3), specificity (TN / [TN
+ FP], see Figure 4.4), positive predictive value (TP / [TP + FP], see Figure 4.5),
negative predictive value (TN / [TN + FN], see Figure 4.6), and Dice similarity
coefficient (2*TP / [(FP + TP) + (TP + FN)], see Figure 4.7). Beyond a comparison
of the lesion area determined by each segmentation method, these performance
measures provide information regarding the degree of spatial overlap between
pixels considered to contain hyperintense or hypointense lesion. Greater sensitivity
indicates a smaller FN detection rate while greater specificity indicates a smaller
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FP rate. Greater PPV indicates that if a rater classifies a pixel as being located in a
lesion, the likelihood that the pixel is actually located in a lesion is increased.
Likewise, great NPV indicates that if a rater classifies a pixel as not being located
in a lesion, the likelihood that the pixel is not actually located in a lesion is
increased. Given two sets of information, the DSC is essentially the ratio of twice
the intersection of the sets to the union of the sets; thus, two completely
overlapping sets would have a DSC of 1 while two sets that do not overlap at all
would have a DSC of 0.
For the histogram-based approach, five different cut-offs were used: mean ±
1.0*SD, mean ± 1.5*SD, mean ± 2.0*SD, mean ± 2.5*SD, and mean ± 3.0*SD. As
can be seen from Figures 4.3 – 4.7, the 1.0*SD cut-off was superior to that of the
other four histogram-based segmentations, as its performance measures were
least often significantly different from those of the human raters. Thus, the 1.0*SD
cut-off was used for determination of lesion size in these studies.
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Figure 4.3 – Sensitivity analysis of raters (four human-based
segmentations and five histogram-based segmentations) for
hyperintense and hypointense lesion. The sensitivity of the histogrambased segmentation using the 1.0 standard deviation cut-off was not
significantly different from that of the human raters, indicating comparable
sensitivity in all regions for each type of lesion. Error bars represent standard
error of the mean.
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Figure 4.4 – Specificity analysis of raters (four human-based
segmentations and five histogram-based segmentations) for
hyperintense and hypointense lesion. The specificity of the histogrambased segmentation using the 1.0 standard deviation cut-off was significantly
smaller than that of the human raters (hyperintense lesion, rostral region,
p<0.004; hypointense lesion, caudal region, p<0.004; hypointense lesion,
rostral region, p<0.001), indicating comparable specificity in the epicenter
region for both types of lesions for each type of lesion. Error bars represent
standard error of the mean.
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Figure 4.5 – Positive predictive value (PPV) analysis of raters (four
human-based segmentations and five histogram-based segmentations)
for hyperintense and hypointense lesion. The PPV of the histogram-based
segmentation using the 1.0 standard deviation cut-off was significantly smaller
than that of the human raters (hypointense lesion, rostral region, p<0.003),
indicating comparable PPV in all other regions for each type of lesion. Error
bars represent standard error of the mean.
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Figure 4.6 – Negative predictive value (NPV) analysis of raters (four
human-based segmentations and five histogram-based segmentations)
for hyperintense and hypointense lesion. The NPV of the histogram-based
segmentation using the 1.0 standard deviation cut-off was not significantly
different from that of the human raters, indicating comparable NPV in all
regions for each lesion type. Error bars represent standard error of the mean.
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Figure 4.7 – Dice similarity coefficient (DSC) analysis of raters (four
human-based segmentations and five histogram-based segmentations)
for hyperintense and hypointense lesion. The DSC of the histogram-based
segmentation using the 1.0 standard deviation cut-off was significantly smaller
than that of the human raters (hypointense lesion, rostral region, p<0.005),
indicating comparable DSC in all other regions for each type of lesion. Error
bars represent standard error of the mean.
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Atrophy
In order to understand the effects of Ang1 on atrophy after spinal cord
injury, on a slice-by-slice basis, the percent difference in cord cross-sectional area
between day 7 post-SCI and days 14 and 28 post-SCI was calculated. This
analysis was performed on an intra-animal rather than intra-group basis, in order to
ensure that the analysis was based on the exact same subgroup of animals (n≥6
animals per group). The results are presented in Figure 4.8 and indicate that,
compared to vehicle, Ang1 did not have an effect on atrophy. Atrophy was greatest
in the epicenter region and increased from day 14 post-SCI to day 28 post-SCI. In
the Ang1 group but not the vehicle group, atrophy significantly increased between
days 7-14 post-SCI and days 7-28 post-SCI (p<0.0005) in the epicenter region. A

% Change in Area

temporal increase in atrophy was not observed in any other region for either group.

Atrophy from day 7 to days 14 and 28
10

Vehicle

Ang1

0
-10
-20
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Epi
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Figure 4.8 – Spinal cord atrophy between day 7 and day 14 post-SCI, and
between day 7 and day 28 post-SCI. A negative percent change indicates
atrophy (reduction in size of parenchyma). No significant difference in atrophy
between the groups was observed in any region for either time point
evaluated (n≥6 animals/group/day). Error bars represent standard error of the
mean.
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Lesion size
Applying the 1.0*SD cut-off, the hyperintense, hypointense, and total lesion
sizes were determined as a fraction of the total cross-sectional area. The results
are presented in Figure 4.9 (hyperintense lesion), Figure 4.10 (hypointense lesion),
and Figure 4.11 (total lesion). A significant decrease in the lesion size (both
hyperintense and total) was observed at the epicenter region at day 28 post-SCI in
the Ang1 group compared to the vehicle group.
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Figure 4.9 – Hyperintense lesion determined by objective histogrambased approach (1.0*standard deviation cut-off). *p<0.003. (n≥6
animals/group/day). Error bars represent standard error of the mean.
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Figure 4.10 – Hypointense lesion determined by objective histogrambased approach (1.0*standard deviation cut-off). (n≥6
animals/group/day). Error bars represent standard error of the mean.
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Figure 4.11 – Total lesion determined by objective histogram-based
approach (1.0*standard deviation cut-off). *p<0.003. (n≥6
animals/group/day). Error bars represent standard error of the mean.
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DISCUSSION
In the absence of a ground truth for determining the lesion size in SCI,
hyperintense and hypointense lesions are manually segmented with (Sundberg,
2009; Qian et al., 2010) or without (Nout et al., 2009) the assistance of objective
absolute thresholds. Despite the best efforts to optimize the image quality,
differences in SNR and signal intensity invariably are present from scan to scan,
necessitating animal-, spatial region-, and time-specific absolute thresholds. This
introduces some bias to the evaluation of lesion size. A histogram-based approach
can consistently and objectively identify pixels whose signal intensity is above or
below a relative threshold, which is based on the mean and standard deviation of
signal intensity, on a slice-by-slice basis. Evaluation of the performance of the
histogram-based approach compared to segmentation by human raters revealed
comparable performance. However, the reference image used in these studies
was obtained from the majority voting rule, which assumes that each rater is
equally good at segmenting lesions and thus assigns a weight of ¼ to each. Newer
methods, such as simultaneous truth and performance level estimation (STAPLE),
allow for the generation of a reference segmentation in the absence of a ground
truth (Warfield et al., 2004). Briefly, the STAPLE technique iteratively estimates the
sensitivity and specificity of various image segmentations that are entered into the
algorithm, with the end result of identifying each segmentation’s sensitivity and
specificity against a hidden ground truth. Use of this approach in future studies
may reveal even more comparable performance between the histogram-based
technique using 1.0*SD cut-off and human raters.
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A significant increase in atrophy was observed from days 7-14 post-SCI to
days 7-28 post-SCI in the Ang1 group. Given that Ang1 has been shown to be
neuroprotective (Onda et al., 2008; Bai et al., 2009; Han et al., 2010), the atrophy
effect observed in this study may be attributable to the single dose of Ang1 that
was administered immediately after SCI. Because the animals scanned at 2 dayspost SCI were not scanned thereafter, we were not able to determine the effect of
Ang1 on atrophy during the acute phase of injury, when the effects of such a dose
may be expected to be significant. Previous studies have determined maximum
atrophy to occur at 14 days post-SCI (Deng et al., 2007) However, in the current
study, the maximum atrophy (based on the 28-day window studied) occurred at 28
days post-SCI in each region in both groups. An ex vivo MRI-based study of
atrophy during the ultrachronic phase of injury determined that atrophy was
maximal at 5 months post-SCI (Scholtes et al., 2008). This may indicate increased
atrophy over time with evolving secondary pathologies (e.g., tissue scarring). In
vivo MRI assessment of atrophy in the late chronic and ultrachronic phases of SCI
will need to be performed in order to validate the post-mortem findings of Scholtes
et al.
In regards to lesion size, an effect of Ang1 in reducing the hyperintense and
total lesion was observed in the epicenter region at 28 days post-SCI. During this
time point (transition from subacute the chronic phase of injury), the hyperintense
signal on the second echo of the RARE MRI scan represents a transition from
edema to demyelination. Thus, a reduced hyperintense lesion at 28 day post-SCI
may indicate preserved white matter. This is consistent with the finding of Han et
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al., who reported significantly reduced white matter loss in Ang1-treated animals
compared to vehicle-treated animals, in the same region (epicenter), at 42 days
post-SCI (Han et al., 2010). However, they also reported an increase at 7 days
post-SCI, which may have occurred due to the daily administration of Ang1 in their
study (Han et al., 2010). Han et al. quantified lesion volume histologically and
reported it to be decreased at 7 days post-SCI in the group of animals that
received daily injections of C-16, a ligand for αvβ3 integrin; similar results for the
Ang1 group were not reported in their study (Han et al., 2010).
Taken together, the results of the atrophy and lesion size analysis indicate
that the effects of an acute administration of Ang1 may not be realized until the
subacute/chronic phase. This is in contrast to the findings in the previous chapter,
in which the effects of Ang1 on reducing BSCB permeability were realized as early
as 2 days post-SCI. This suggests that the established effects of Ang1 on vascular
endothelium take place closer to the time of administration, while perhaps its
indirect effects may not be realized until later. For example, Ang1 has been shown
to reduce inflammation through inhibition of NF-κB via ABIN-2 (Hughes et al.,
2003). Although reduced inflammation may result in decreased demyelination
indirectly and in a delayed fashion, the direct effects on vascular endothelium are
more pronounced (Tadros et al., 2003). An alternate explanation for the delayed
effect of Ang1 on reducing lesion size, despite reducing BSCB permeability as
early as 2 days post-SCI, is that the dose of Ang1 was not sufficient for its antiinflammatory effects to be significant in the acute phase of injury. Using daily
injections of Ang1 after SCI, Han et al. demonstrated that an increased and
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sustained dose of Ang1 can lead to a reduction in white matter loss (i.e.,
decreased lesion size) in both the acute and chronic phases of injury (Han et al.,
2010).
As another example, Ang1 has been shown to reduce the expression of cell
adhesion molecules, e.g. intercellular adhesion molecule 1 (ICAM-1), which
facilitate the adhesion and subsequent transendothelial migration of leukocytes
(Kim et al., 2001) into the injured cord. Studies that directly target ICAM-1, which
has been shown to be endogenously upregulated in SCI (Isaksson et al., 1999),
have demonstrated improved neurobehavioral recovery (Hamada et al., 1996;
Farooque et al., 1999) and white matter preservation (Farooque et al., 2001) after
injury. In the absence of histological assessment in the current studies, the effects
of a single dose of Ang1 on ICAM-1 expression is unknown. Even if a role for
Ang1-mediated reduction in ICAM-1 expression after SCI were to exist, the
benefits of directly targeting ICAM-1 observed in previous studies was not
observed in this study. This highlights the fact that, despite mitigating various
known secondary pathologies of SCI, Ang1’s most immediate effect in the current
study was in the context of reducing vascular permeability.
In summary, the results indicate that, at 28 days post-SCI, a single acute
dose of Ang1 reduces lesion size at the epicenter of injury. The methods used in
these studies can be applied in other models of spinal cord injury, which may
enable consistent reporting of results that will allow for meaningful comparative
analysis across studies.
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Limitations
The results of these studies should be considered in the context of its
limitations. First, the STAPLE method was not used to establish the ground truth
reference image based on the human rater segmentations. Although the STAPLEbased reference image may not be significantly different than the one used in
these studies (due to the small number of pixels encompassed by the rat spinal
cord), plans are underway to employ this approach and re-assess the performance
of the histogram-based technique. Second, the analysis of lesion size was not
completely automated because the CSF and surrounding tissue were manually
stripped from the spinal cord prior to analysis. Although methods for automated
stripping have been reported (Deng et al., 2007), they still require an initial humanbased input (seed point). Nonetheless, full automation of the proposed method
would further reduce any possible bias introduced by user intervention.
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CHAPTER 5:

EFFECT OF SINGLE ACUTE ANG1 DOSE ON AXONAL INTEGRITY AND
NEUROBEHAVIORAL RECOVERY AND LONGITUDINAL CORRELATION
WITH LESION SIZE
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INTRODUCTION
Reduced axonal integrity and demyelination are major consequences of
spinal cord injury that affect motor function (Blight, 1985; Waxman, 1992; Hagg
and Oudega, 2006; McDonald and Belegu, 2006). Therapeutic remyelination
approaches have been studied in the context of spinal cord injury (Klussmann and
Martin-Villalba, 2005; Sasaki et al., 2007; McTigue and Tripathi, 2008; Wu and
Ren, 2009). In fact, the first study to receive FDA approval for the treatment of
human SCI involves intraspinal injection of oligodendrocyte progenitor cells that
are hypothesized to assist with the process of axonal remyelination (Couzin, 2009).
Diffusion tensor imaging, a MRI modality, allows for the evaluation of axonal
integrity and has been applied in the context of spinal cord injury (Fenyes and
Narayana, 1999; Madi et al., 2005; Deo et al., 2006). A high mean diffusivity (MD),
defined as the average diffusivity in the three primary orthogonal directions (λ1, λ2,
and λ3), indicates a lack of structure that enables water molecules to diffuse in a
non-preferential manner. Coupled with high MD, low fractional anisotropy (FA, an
indicator of the diffusion anisotropy that reflects the orderliness of tissue structure)
are indicative of poor axonal integrity. On the other hand, low MD in the presence
of high FA is indicative of high axonal integrity. MD can be subdivided further into
longitudinal diffusivity (λL = λ1) and transverse diffusivity (λT = 0.5*λ2 + 0.5* λ3).
Although λT and λL have been shown to be correlated with demyelination and
axonal damage, respectively (Budde et al., 2007; Herrera et al., 2007), controversy
remains in the literature regarding the specificity of these DTI measures for white
matter pathology. Due to the highly organized nature of axons comprising the
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fibers of white matter tracts and the impedance provided by myelin, λL > λT (Hasan
and Narayana, 2006).
In the assessment of white matter pathology after SCI, correlations between
axonal integrity and measures from neurobehavioral assessments can be used to
probe structure-function relationships. Such assessments include the open-field
BBB locomotor assay (Basso et al., 1995), inclined plane test for evaluating axial
muscle strength and control of posture (Rivlin and Tator, 1977), grid walk test for
assessment of hindlimb-forelimb sensory and motor coordination (Bresnahan et
al., 1987), and computerized activity box system for testing of gross motor
movement (i.e., ambulation), fine motor movement, and rearing (Mills et al., 2001).
Neurosensory assessment of mechanical allodynia is assessed with the von Frey
filament (Peng et al., 2006).
The purpose of these studies was to evaluate the effects of acutely
administered Ang1 on axonal integrity, neurobehavioral recovery, and neuropathic
pain during the subacute and chronic phases of spinal cord injury, with additional
assessment of possible correlations among neurobehavioral and MRI measures.
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RESULTS
DTI measures
Table 5.1 summarizes the inter-group significant differences in mean
diffusivity values in the four ROIs described in the methodology chapter (dorsal,
CST, lateral, and ventral), by days post-SCI and spatial region. Mean diffusivity
was significantly greater in the Ang1 group during the subacute phase but
significantly greater in the vehicle group during the chronic phase.
ROI

Days
post-SCI

Spatial
Region

Vehicle

Operator

Ang1

p-value

0.00069±
0.00088±
<
p<0.003
0.000045
0.000054
Dorsal
0.0017±
0.00098±
56
Epicenter
>
p<0.0008
0.00014
0.000091
0.00093±
0.00050±
56
Caudal
>
p<0.007
0.00015
0.000044
CST
0.0017±
0.00087±
56
Epicenter
>
p<0.0003
0.00016
0.000095
0.00069±
0.00095±
7
Epicenter
<
p<0.00001
0.000030
0.000050
0.00072±
0.00092±
7
Rostral
<
p<0.016
0.000033
0.000057
Lateral
0.00069±
0.00092±
14
Epicenter
<
p<0.00001
0.000043
0.000029
0.00078±
0.00093±
14
Rostral
<
p<0.0008
0.000050
0.000025
0.00069±
0.00096±
Ventral
14
Epicenter
<
p<0.00001
0.000041
0.000038
Table 5.1 – Summary of significant inter-group differences in mean diffusivity
(units: mm2s-1). Ang1 = angiopoietin-1, CST = corticospinal tract, SCI = spinal
cord injury. (n≥6 animals/group/day). Data are presented as mean±standard error
of the mean.
7

Epicenter
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Table 5.2 summarizes the significant differences in fractional anisotropy
between the two groups. Converse to the findings in MD, FA was significantly
reduced in the Ang1 group during the subacute phase but significantly greater in
the Ang1 group during the chronic phase. The findings in FA and MD are
complementary in that reduced MD with concomitantly increased FA is indicative of
higher axonal integrity, whereas increased MD with concomitantly reduced FA is
indicative of poor axonal integrity. Taken together, in the Ang1 group compared to
vehicle group, these findings indicate reduced axonal integrity during the subacute
phase and increased axonal integrity during the chronic phase.
Days
Spatial
Vehicle Operator
Ang1
p-value
post-SCI
Region
Dorsal
42
Epicenter
0.22±0.04
<
0.40±0.04 p<0.004
7
Rostral
0.61±0.02
>
0.41±0.04 p<0.00001
Lateral
14
Epicenter
0.47±0.03
>
0.36±0.02 p<0.011
7
Rostral
0.65±0.03
>
0.50±0.03 p<0.003
Ventral
14
Rostral
0.64±0.03
>
0.52±0.03 p<0.0165
Table 5.2 – Summary of significant inter-group differences in fractional
anisotropy (unitless). Ang1 = angiopoietin-1, CST = corticospinal tract, SCI =
spinal cord injury. (n≥6 animals/group/day). Data are presented as mean±standard
error of the mean.
ROI
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Table 5.3 summarizes the significant differences in longitudinal diffusivity
between the two groups. Consistent with the temporal pattern observed for MD in
the Ang1 group, λL was significantly greater in the subacute phase and significantly
reduced in the chronic phase.

ROI

Days
post-SCI

Spatial
Region

Vehicle

Operator

Ang1

p-value

0.00094±
<
0.00120± p<0.002
0.00007
0.00010
Dorsal
0.00203±
>
0.00121± p<0.0004
56
Epicenter
0.00016
0.00011
0.00126±
>
0.00077± p<0.012
56
Caudal
0.00017
0.00004
CST
0.00202±
>
0.00118± p<0.0003
56
Epicenter
0.00017
0.00012
0.00104±
<
0.00132± p<0.003
7
Epicenter
0.00007
0.00009
0.00104±
<
0.00132± p<0.0003
14
Epicenter
0.00007
0.00006
Lateral
0.00131±
<
0.00160± p<0.002
14
Rostral
0.00009
0.00006
0.00197±
>
0.00164± p<0.006
56
Epicenter
0.00007
0.00009
0.00099±
<
0.00140± p<0.0008
Ventral
14
Epicenter
0.00008
0.00009
Table 5.3 – Summary of significant inter-group differences in longitudinal
diffusivity (units: mm2s-1). Ang1 = angiopoietin-1, CST = corticospinal tract, SCI
= spinal cord injury. (n≥6 animals/group/day). Data are presented as
mean±standard error of the mean.
7

Epicenter
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Table 5.4 summarizes the significant differences in transverse diffusivity
between the two groups. As was the case with MD and λL in the Ang1 group, λT
was significantly increased in the subacute phase and significantly reduced during
the chronic phase.
ROI

Days
post-SCI

Spatial
Region

Vehicle

Operator

Ang1

p-value

0.00056±
<
0.00073± p<0.004
0.00003
0.00005
0.00045±
<
0.00061± p<0.016
Dorsal
14
Caudal
0.00005
0.00005
0.00146±
>
0.00087± p<0.002
56
Epicenter
0.00014
0.00009
0.00076±
>
0.00036± p<0.012
CST
56
Caudal
0.00015
0.00005
0.00155±
>
0.00072± p<0.0004
56
Epicenter
0.00016
0.00009
0.00052±
<
0.00076± p<0.00001
7
Epicenter
0.00002
0.00004
Lateral
0.00042±
<
0.00070± p<0.00001
7
Rostral
0.00002
0.00005
0.00051±
<
0.00072± p<0.00001
14
Epicenter
0.00004
0.00003
0.00050±
<
0.00072± p<0.003
7
Epicenter
0.00003
0.00007
0.00054±
<
0.00075± p<0.00001
Ventral
14
Epicenter
0.00003
0.00003
0.00049±
<
0.00061± p<0.007
14
Rostral
0.00006
0.00003
Table 5.4 – Summary of significant inter-group differences in transverse
diffusivity (units: mm2s-1). Ang1 = angiopoietin-1, CST = corticospinal tract, SCI
= spinal cord injury. (n≥6 animals/group/day). Data are presented as
mean±standard error of the mean.
7

Epicenter

The results of analysis of the DTI measures indicate that a single
administration of Ang1 in the acute phase of injury resulted in reduced axonal
integrity during the subacute phase but improved axonal integrity during the
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chronic phase. Functional correlates of WM integrity, i.e., neurobehavioral
recovery, are presented in the next section.

Neurobehavioral assays
Figure 5.1 displays the BBB scores over time. The BBB score was
significantly increased in the Ang1 group at 2 days post-SCI and 3 days post-SCI.
These results provide evidence for an Ang1 treatment effect on neurobehavioral
recovery in the acute phase of injury.

Vehicle
Ang1

BBB Score
BBB Score

25
20
15
10
5

*

*

0
preSCI

2

3

7

14

28

42

56

Days post-SCI

Figure 5.1 – Basso-Beattie-Bresnahan (BBB) score. (n≥6 animals/group for
2-day assessment and n≥9 animals/group for all other days). Error bars
represent standard error of the mean. Ang1 = angiopoietin-1, SCI = spinal cord
injury.
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Figure 5.2 displays the inclined plane assessment results over time. There
was no significant difference between the groups at any time point.

Inclined Plane Assay
Angle (deg.)

80

Vehicle
Ang1

60
40
20
0
pre-SCI

14

28

42

56

Days post-SCI
Figure 5.2 – Inclined plane assessment. (n≥9 animals/group/day). Error
bars represent standard error of the mean. Ang1 = angiopoietin-1, SCI =
spinal cord injury.
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Figure 5.3 displays the grid walk results over time. There was no significant
difference between the groups at any time point. It is important to note that for this
assay, a smaller value is beneficial (i.e., improved sensory-motor integration
between hindlimbs and forelimbs would lead to a reduction in foot falls as the rats
traverse the mesh grid).

Vehicle
Ang1

Grid Walk Assay
% Foot Falls

60%
40%
20%
0%
pre-SCI

14

28

42

56

Days post-SCI
Figure 5.3 – Grid walk assessment. (n≥9 animals/group/day). Error bars
represent standard error of the mean. Ang1 = angiopoietin-1, SCI = spinal
cord injury.
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Figure 5.4 displays the computerized activity box results over time. There
was no significant difference between the groups at any time point for any of the
measures (ambulation distance, fine movement, and number of rearing events).

Ambulation Distance
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Number of Rearing Events
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40
20
0
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14

28

42
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Days post-SCI
Figure 5.4 – Computerized activity box assessment. (n≥9
animals/group/day). Error bars represent standard error of the mean. Ang1 =
angiopoietin-1, SCI = spinal cord injury.
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Previous studies have implicated a role for neurotrophin-3 and vascular
endothelial growth factor (VEGF) in the induction of neuropathic pain in models of
peripheral nerve injury and spinal cord injury, respectively (Deng et al., 2000;
Sundberg, 2009). In the latter study, VEGF’s role in causing chronic neuropathic
pain (defined in the Materials and Methods chapter) was attributed to preservation
of nociceptive neurons in tissue spared by VEGF treatment (Sundberg, 2009).
Figure 5.5 displays the results of the von Frey hair test for chronic neuropathic
pain. There was no significant difference in prevalence of chronic pain between the
two groups. This is an interesting finding in the context of the results of the
previous chapter, in which Ang1 was shown to reduce lesion volume in the chronic
phase of injury.

Chronic Pain
Chronic Pain Prevalence

25%
20%
15%
10%
5%
0%
Vehicle (n=9)

Group

Angiopoietin-1 (n=11)

Figure 5.5 – Assessment of chronic neuropathic pain. No significant
difference based on chi-square analysis. (n≥9 animals/group/day).
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Longitudinal correlations
Generalized estimating equation (GEE) method was employed to assess for
significant correlations between lesion size, MD, FA, λL, λT, and BBB scores. The
significant longitudinal correlations between the BBB score and DTI and RARE
MRI measures are presented in Table 5.5. Significant positive correlations
between BBB score and the DTI measures of MD, λL, and λT were observed in the
epicenter region of vehicle-treated animals. In the epicenter and caudal regions of
Ang1-treated animals, hyperintense, hypointense, and total lesion size as a
percent of spinal cord cross-sectional area negatively correlated with BBB score.
This was also the case for vehicle-treated animals but only in for hyperintense
lesion in the rostral region.

Correlation Between
BBB score and:

Spatial
Sign of
p-value
Region Correlation
Ang1
Caudal
Negative
p<0.012
Hyperintense lesion
Vehicle
Rostral
Negative
p<0.004
Ang1
Caudal
Negative
p<0.007
Hypointense lesion
Ang1
Epicenter Negative
p<0.0001
Ang1
Caudal
Negative
p<0.003
Total lesion
Ang1
Epicenter Negative
p<0.0001
MD in CST ROI
Vehicle
Epicenter Positive
p<0.0001
λL in CST ROI
Vehicle
Epicenter Positive
p<0.0001
λT in CST ROI
Vehicle
Epicenter Positive
p<0.0001
Table 5.5 – Significant longitudinal correlations between Basso-BeattieBresnahan (BBB) score and measures from high-resolution anatomical
and diffusion tensor imaging scans. Ang1 = angiopoietin-1, CST =
corticospinal tract, MD = mean diffusivity, λL = longitudinal diffusivity, λT =
transverse diffusivity. (n≥6 animals/group/day).
Group
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Table 5.6 summarizes the significant longitudinal correlations between
lesion sizes and DTI measures in the CST. In both groups, hyperintense lesion
size positively correlated with hypointense lesion size in each of the three spatial
regions. In regards to anatomical-DTI MRI correlations, these were significant only
for hyperintense lesions, which positively correlated with MD, λL, and λT, and
negatively correlated with FA.

Spatial
Correlation
p-value
Region
Ang1
Caudal
Positive
p<0.012
Ang1
Epicenter
Positive
p<0.0001
Hypointense
Vehicle
Caudal
Positive
p<0.003
lesion
Vehicle
Epicenter
Positive
p<0.0001
Vehicle
Rostral
Positive
p<0.0001
Ang1
Caudal
Positive
p<0.0001
Ang1
Epicenter
Positive
p<0.0001
Hyperintense
Ang1
Rostral
Positive
p<0.0001
Total lesion
lesion
Vehicle
Caudal
Positive
p<0.0001
Vehicle
Epicenter
Positive
p<0.0001
Vehicle
Rostral
Positive
p<0.0001
FA in CST
Ang1
Epicenter
Negative
p<0.0001
MD in CST
Vehicle
Epicenter
Positive
p<0.002
Ang1
Caudal
Positive
p<0.011
λL in CST ROI
Vehicle
Epicenter
Positive
P<0.003
λT in CST ROI
Vehicle
Epicenter
Positive
p<0.002
Ang1
Caudal
Positive
p<0.0001
Ang1
Epicenter
Positive
p<0.0001
Hypointense
Ang1
Rostral
Positive
p<0.0001
Total lesion
lesion
Vehicle
Caudal
Positive
p<0.0001
Vehicle
Epicenter
Positive
p<0.0001
Vehicle
Rostral
Positive
p<0.0001
Table 5.6 – Significant longitudinal correlations between lesion measures and
diffusion tensor imaging measures. Ang1 = angiopoietin-1, CST = corticospinal tract,
FA = fractional anisotropy, MD = mean diffusivity, λL = longitudinal diffusivity, λT =
transverse diffusivity. (n≥6 animals/group/day).
Measure 1

Measure 2

Group

Summary of results
The DTI, neurobehavioral, and correlational analysis studies described in
this chapter indicate that Ang1 administration improves neurobehavioral recovery
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in the acute phase of injury, transiently results in reduced axonal integrity during
the subacute phase of injury, and improve axonal integrity during the chronic
phase. The hyperintense lesion, which was shown in the previous chapter to be
significantly reduced during the chronic phase in the Ang1 group, was negatively
correlated with FA, a measure of axonal integrity. Finally, despite Ang1-mediated
tissue sparing in the chronic phase, chronic neuropathic pain was not observed in
this study.
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DISCUSSION
Overall, these findings indicate a pattern of reduced axonal integrity in the
Ang1 group in the subacute phase (decreased FA and increased MD compared to
control) and a pattern of improved axonal integrity in the chronic phase (increased
FA and decreased MD compared to control). However, when the MD is subdivided
into its constituent components of λL and λT, the pattern is not as clear. This may
be due to the role of multiple modulators of λL and λT beyond axonal integrity and
myelination status, respectively. For example, although much focus of the role of
Ang1 is placed on its effects on vascular endothelium, neuronal cells that express
Tie-2 have been shown to be directly affected by Ang1. In cultured dorsal root
ganglion cells exposed to Ang1, Kosacka et al. observed neurite outgrowth (socalled “sprouting”) (Kosacka et al., 2005; Kosacka et al., 2006) in cells expressing
Tie-2. There is also evidence from studies in cultured PC12 cells (modified
postganglionic neurons in the medulla of rat adrenal glands) that Ang1 induces
sprouting in a Tie-2-independent but β1-integrin-dependent manner (Chen et al.,
2009). At the microscopic level, such outgrowth of unmyelinated neurites at
different angles relative to the primary axon could contribute to the decreased FA
observed in the Ang1 group in the subacute phase. During this phase of injury, the
concomitant increase in λL and λT in the Ang1 group indicates increased diffusion
both parallel and perpendicular to the axon. Angiopoietin-1 has also been shown to
be neuroprotective via different mechanisms, including prevention of neuronal
apoptosis (Valable et al., 2003), promotion of neurogenesis (Rosa et al., 2010),
and triggering neuroblast migration to damaged CNS tissue (Ohab et al., 2006).
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Although changes in λL and λT are traditionally thought to be complementary in
moderate contusion SCI, i.e. reduced λL and increased λT (Ellingson et al., 2008),
the neuroprotective and sprouting effects of Ang1 may result in simultaneously
increased λL and λT, as was observed in this study.
In two separate cohorts of animals (those used for the acute study and
those for the longitudinal study), Ang1 was found to result in improved locomotor
recovery during the acute phase. After administering daily injections of Ang1 in a
mouse model of SCI, Han et al. reported improved locomotor recovery at days 742 post-SCI (Han et al., 2010). These findings suggest that prolonged Ang1
administration beyond a single acute time point may facilitate improved locomotor
recovery in our experimental model during the subacute and chronic phases of
injury. Another notable finding of the neurobehavioral analysis in this study was the
lack of difference in chronic pain between both groups, despite a significant
preservation of tissue in the Ang1 group as shown in the previous chapter.
Sundberg reported an exacerbation of chronic pain in SCI rats treated with
vascular endothelial growth factor (VEGF), which also reduced lesion size
compared to her control group (Sundberg, 2009).

She postulated that the

increased chronic pain in VEGF-treated animals was attributable to the
preservation of nociceptive neurons in the tissue salvaged by VEGF therapy
(Sundberg, 2009). These results suggest that Ang1 exposure post-SCI may result
in the neuromotor benefit of tissue preservation without the unwanted
consequence of chronic neuropathic pain, which is part of a spectrum of pain
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conditions experienced by up to 80% of patients suffering from spinal cord injury
(Hulsebosch et al., 2009).
Gullapalli et al. have previously evaluated white matter tracts in uninjured rat
spinal cord (Gullapalli et al., 2006). In the present study, the corticospinal tract was
segmented in addition to those previously reported (Deo et al., 2006; Sundberg,
2009) in order to determine any potential correlations between DTI measures in
this critical tract and the BBB open-field locomotor score. Longitudinal correlational
analysis with GEE method revealed a significant positive correlation between BBB
score and MD, λL, and λT. While the correlation with λL may be intuitive, that with
MD and λT may not be, because increased λT has previously been reported to be
correlated with demyelination (Herrera et al., 2007). This again points to the
possible contributions of other processes (e.g. neurite sprouting) to alterations in
DTI measures after spinal cord injury.
In the Ang1 group, the hyperintense lesion was positively correlated with λL
and negatively correlated with FA. The reduced extent of edema (acute phase) or
demyelination (subacute and chronic phases) as evidenced by decreased lesion
size in the Ang1 group (previous chapter) may account for the positive correlation.
The BBB score was also found to be negatively correlated with total lesion size in
the epicenter region of the Ang1 group, which is consistent with Han et al.’s finding
of a positive correlation between locomotor score and white matter preservation
(Han et al., 2010).
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Limitations
The novel DTI-based findings in the corticospinal tract, longitudinal
correlations between behavioral and MRI-based measures, and lack of chronic
neuropathic pain despite tissue sparing are the main contributions of these studies.
The results should also be considered in the context of the study’s limitations.
Longitudinally scanning the animals in order to ensure reporting of in vivo
measures is a double-edged sword in that histological analysis can not be
performed and correlated with MRI measures at serial time points to provide a
biological context to the findings on MRI. Given that an interesting transient
reduction in axonal integrity during the subacute phase was observed in the Ang1
group, histological assessment of possible determinants of altered λL and λT during
this phase of injury would be helpful in broadening our understanding of the
meaning of the changes in these DTI measures.
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CHAPTER 6:

CONCLUSIONS AND FUTURE STUDIES
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The purpose of these studies was to determine the effects of a single dose
of Ang1 administered immediately after spinal cord injury in a rat model of
contusion SCI. The summary of results is presented in Table 6.1
SCI
BSCB
Axonal
Lesion Neurobehavioral
Phase
integrity
Assessment
Acute (2-3
↓ Frank enhancement Not
↑ BBB score
days post-SCI) ↓ Permeability
studied
Subacute (7-14 ↓ Frank enhancement ↓ FA, ↑ MD
days post-SCI) ↓ Permeability
↑ λL, ↑ λT
Chronic (28-56 ↓ Frank enhancement ↑ FA, ↓ MD ↓ Lesion
day post-SCI) ↓ Permeability
↓ λL, ↓ λT
Table 6.1 - Summary of study findings. BBB = Basso-Beattie-Bresnahan
score, BSCB = blood-spinal cord barrier, FA = fractional anisotropy, MD = mean
diffusivity, SCI = spinal cord injury, λL = longitudinal diffusivity, λT = transverse
diffusivity.

In the acute phase of injury, Ang1 resulted in a reduction in BSCB permeability and
the fraction of spinal cord tissue with visually apparent BSCB compromise, and an
improvement in the BBB score. In the subacute phase, Ang1’s effects on the
BSCB were maintained but Ang1 resulted in reduced axonal integrity and the
improvement in BBB score was not maintained. In the chronic phase, the effects of
Ang1 on the BSCB were maintained and Ang1 resulted in improved axonal
integrity with no difference in behavioral outcomes.
Ang1 has been shown to target various components of the BSCB (e.g.,
occludin (Iizasa et al., 2002; Hori et al., 2004; Wang et al., 2007), vascular
endothelial cadherin (Gavard et al., 2008; Mochizuki, 2009), vascular endothelial
cells (Thurston et al., 1999; Thurston et al., 2000), and the glycocalyx (Salmon et
al., 2009)), resulting in reduced permeability. In addition, Ang1 has been shown to
mediate neuroprotective effects on neuronal cells directly (Ohab et al., 2006; Chen
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et al., 2009). Because the BSCB is a part of the neurovascular unit (Choi and Kim,
2008), its compromise leads to a number of pathological events, including
hemorrhage (via mechanical trauma to the vessels), edema (via extravasation of
plasma

proteins),

inflammation

/

free-radical

production

(via

neutrophil

transendothelial migration), and neuronal apoptosis (via vasospasm and ischemia).
The differential effects of Ang1 on the vascular endothelium and neuronal tissue
may be mediated through different signaling pathways, each of which involves
Ang1 as a ligand. Figure 6.1 summarizes the findings in pictorial form.

Figure 6.1 - Summary of findings. Ang1 = angiopoietin-1, BSCB = bloodspinal cord barrier, FA =fractional anisotropy, λT = transverse diffusivity.
A major limitation of these studies is the lack of histological validation of the
findings of the various MRI modalities. We have previously shown with qualitative
histology that the DCE-MRI Kps parameter is reflective of the extent of albumin
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extravasation into the spinal cord (Patel et al., 2009). Correlations between lesions
identified on high-resolution anatomical MRI scans have also been identified with
histological markers of inflammation (Bilgen et al., 2000; Bilgen et al., 2007). In
regards to DTI measures, although controversy remains regarding the specificity of
λL and λT for axonal integrity and myelination status (Budde et al., 2007; Herrera et
al., 2007), the seemingly counter-intuitive nature of findings in these metrics
observed here may be elucidated with histological analysis. In addition, DTI
acquisition during the acute phase of injury may be considered, as DTI measures
in the hyperacute phases have been reported to be predictive of locomotor
recovery in the chronic phase (Kim et al., 2010).
In regards to neurobehavioral assessment, a lack of chronic pain in the
Ang1 group despite tissue sparing, as reflected by the reduced lesion size, is
important in the context of previous findings of VEGF-induced chronic neuropathic
pain (Sundberg, 2009) with concomitant tissue sparing. Unlike VEGF, Ang1
reduces vascular permeability and is not a potent promoter of angiogenesis.
However, when used in concert with VEGF, Ang1 has been shown to normalize
vasculature, providing an environment for non-hyperpermeable, “therapeutic”
angiogenesis (Zacharek et al., 2007; Hansen et al., 2008; Toyama et al., 2009;
Zhao et al., 2009).
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Future studies
A consideration for future studies is the role of integrins in SCI. Coadministration of Ang1 and C16 peptide, a ligand for αvβ3 integrin, was shown to
be synergistic in regards to locomotor recovery in the subacute phase but not in
the chronic phase of SCI (Han et al., 2010). Although synergy was not observed in
regards to white matter sparing or reduced markers of inflammation on histology in
the acute and chronic phases in their study, delivering Ang1 in combination with
other agents that stimulate pro-survival pathways (e.g., PI3K) in different tissues
(e.g., vascular endothelium and neurons) may be another therapeutic avenue to
consider in the context of spinal cord injury.
Investigations into the temporal expression of endogenous Ang1 after SCI
will be necessary in order to identify the time windows when supplementation with
exogenous Ang1 may be warranted. The single dose of Ang1 in this study appears
to have resulted in effects during all phases of injury, most prominently during the
acute and subacute phases. Thus, it would be desirable in future studies to focus
on these periods of injury and perform MRI-histological correlations at serial time
points, in order to understand the effects of Ang1 during these phases of injury. In
light of the study by Han et al. (Han et al., 2010), the dose and timing of Ang1
administration in this study are two variables that could be optimized. Future
studies will use viral vectors encoding Ang1 that are injected into the injury lesion
in order to investigate the effects of sustained Ang1 administration in SCI.
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